PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23583259-4	2013	In transiently transfected HepG2 cells, rilpivirine, etravirine, and efavirenz, but not nevirapine or delavirdine, activated human, mouse, and rat PXR.	efavirenz	69-78	nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus	147-150
23583259-6	2013	Rilpivirine, etravirine, and efavirenz, but not nevirapine or delavirdine, increased hPXR target gene (CYP3A4) expression in primary cultures of human hepatocytes.	efavirenz	29-38	nuclear receptor subfamily 1 group I member 2	Homo sapiens	85-89
23583259-6	2013	Rilpivirine, etravirine, and efavirenz, but not nevirapine or delavirdine, increased hPXR target gene (CYP3A4) expression in primary cultures of human hepatocytes.	efavirenz	29-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-109
23583259-8	2013	Rilpivirine, etravirine, and efavirenz, but not nevirapine or delavirdine, were identified as agonists of hPXR, as assessed in mechanistic experiments, and inducers of CYP3A4, as determined in primary cultures of human hepatocytes.	efavirenz	29-38	nuclear receptor subfamily 1 group I member 2	Homo sapiens	106-110
23583259-8	2013	Rilpivirine, etravirine, and efavirenz, but not nevirapine or delavirdine, were identified as agonists of hPXR, as assessed in mechanistic experiments, and inducers of CYP3A4, as determined in primary cultures of human hepatocytes.	efavirenz	29-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	168-174
23563240-4	2013	EFV treatment led to cell proliferation arrest and cell death of the NHKs by inducing autophagy mediated by proteasome-dependent degradation of p53.	efavirenz	0-3	tumor protein p53	Homo sapiens	144-147
23563240-5	2013	EFV also reduced the levels of mTOR and active ERK signaling in NHKs.	efavirenz	0-3	mechanistic target of rapamycin kinase	Homo sapiens	31-35
23467454-3	2013	Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone.	efavirenz	85-94	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
23372109-8	2013	For patients receiving previously efavirenz, there was a significant reduction in TC (-23 mg/dL; -13%) and LDL-C (-25 mg/dL; -21%) levels and a trend to a better TG level (-38 mg/dL; -21%;P = .06).	efavirenz	34-43	component of oligomeric golgi complex 2	Homo sapiens	107-112
23385314-2	2013	The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 microM in HLMs and K(i) = 1.38 microM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 microM in pooled HLMs and K(i) = 4.80 microM in HLMs with CYP2C8*3/*3 genotype).	efavirenz	30-39	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	78-84
23385314-2	2013	The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 microM in HLMs and K(i) = 1.38 microM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 microM in pooled HLMs and K(i) = 4.80 microM in HLMs with CYP2C8*3/*3 genotype).	efavirenz	30-39	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	157-163
23385314-2	2013	The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 microM in HLMs and K(i) = 1.38 microM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 microM in pooled HLMs and K(i) = 4.80 microM in HLMs with CYP2C8*3/*3 genotype).	efavirenz	30-39	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	169-175
23385314-2	2013	The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 microM in HLMs and K(i) = 1.38 microM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 microM in pooled HLMs and K(i) = 4.80 microM in HLMs with CYP2C8*3/*3 genotype).	efavirenz	30-39	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	247-253
23385314-3	2013	Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 microM) and CYP2C19 (K(i) = 21.31 microM); and a weak inhibitor of CYP3A (K(i) = 40.33 microM).	efavirenz	0-9	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	38-44
23385314-3	2013	Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 microM) and CYP2C19 (K(i) = 21.31 microM); and a weak inhibitor of CYP3A (K(i) = 40.33 microM).	efavirenz	0-9	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	71-78
23385314-3	2013	Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 microM) and CYP2C19 (K(i) = 21.31 microM); and a weak inhibitor of CYP3A (K(i) = 40.33 microM).	efavirenz	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-131
25505649-2	2013	Artemether is a substrate of CYP3A4 and CYP2B6, antiretrovirals such as efavirenz induce these enzymes and have the potential to reduce artemether pharmacokinetic exposure.	efavirenz	72-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35
25505649-2	2013	Artemether is a substrate of CYP3A4 and CYP2B6, antiretrovirals such as efavirenz induce these enzymes and have the potential to reduce artemether pharmacokinetic exposure.	efavirenz	72-81	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	40-46
23302874-1	2013	Efavirenz (EFV), a nonnucleoside reverse transcriptase (RT) inhibitor, also inhibits HIV-1 particle release through enhanced Gag/Gag-Pol processing by protease (PR).	efavirenz	0-9	Pr55(Gag)	Human immunodeficiency virus 1	125-128
23302874-1	2013	Efavirenz (EFV), a nonnucleoside reverse transcriptase (RT) inhibitor, also inhibits HIV-1 particle release through enhanced Gag/Gag-Pol processing by protease (PR).	efavirenz	0-9	Gag-Pol	Human immunodeficiency virus 1	129-136
23302874-1	2013	Efavirenz (EFV), a nonnucleoside reverse transcriptase (RT) inhibitor, also inhibits HIV-1 particle release through enhanced Gag/Gag-Pol processing by protease (PR).	efavirenz	11-14	Pr55(Gag)	Human immunodeficiency virus 1	125-128
23302874-1	2013	Efavirenz (EFV), a nonnucleoside reverse transcriptase (RT) inhibitor, also inhibits HIV-1 particle release through enhanced Gag/Gag-Pol processing by protease (PR).	efavirenz	11-14	Gag-Pol	Human immunodeficiency virus 1	129-136
23302874-2	2013	To better understand the mechanisms of the EFV-mediated enhancement of Gag processing, we examined the intracellular localization of Gag/Gag-Pol processing products and their precursors.	efavirenz	43-46	Pr55(Gag)	Human immunodeficiency virus 1	71-74
23302874-2	2013	To better understand the mechanisms of the EFV-mediated enhancement of Gag processing, we examined the intracellular localization of Gag/Gag-Pol processing products and their precursors.	efavirenz	43-46	Pr55(Gag)	Human immunodeficiency virus 1	133-136
23302874-2	2013	To better understand the mechanisms of the EFV-mediated enhancement of Gag processing, we examined the intracellular localization of Gag/Gag-Pol processing products and their precursors.	efavirenz	43-46	Gag-Pol	Human immunodeficiency virus 1	137-144
23302874-7	2013	Forster"s fluorescence resonance energy transfer assay revealed that Gag-Pol precursor dimerization occurred mainly at the PM and that EFV induced a significant increase of the Gag-Pol dimerization at the PM.	efavirenz	135-138	Gag-Pol	Human immunodeficiency virus 1	177-184
23254426-0	2013	Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.	efavirenz	92-101	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	37-43
22642697-9	2013	CONCLUSION: CYP3A inducers, rifampicin and efavirenz, can reduce telaprevir exposure to varying degrees based on their potency.	efavirenz	43-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-17
23640958-0	2013	Efavirenz intoxication due to a new CYP2B6 constellation.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	36-42
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	14-17	glycogen synthase kinase 3 beta	Homo sapiens	40-71
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	14-17	glycogen synthase kinase 3 beta	Homo sapiens	73-81
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	14-17	glycogen synthase kinase 3 beta	Homo sapiens	147-155
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	249-252	glycogen synthase kinase 3 beta	Homo sapiens	73-81
23133441-3	2012	The aim of the study was to evaluate the role of polymorphisms in ABCB1 gene on plasma efavirenz levels and treatment response in the form of change in viral load and CD-4 cell count in HIV/AIDS patients receiving efavirenz-containing highly active antiretroviral treatment regimens.	efavirenz	87-96	ATP binding cassette subfamily B member 1	Homo sapiens	66-71
23372824-8	2013	Children receiving EFV experienced increases in both CD4(+) T-cell percentage and weight-for-age z-score during follow-up, such that levels were comparable to children receiving NVP after two years of ART.	efavirenz	19-22	CD4 molecule	Homo sapiens	53-56
22950382-11	2012	CYP2B6-516G > T polymorphism was the only factor associated with high plasma EFV levels.	efavirenz	80-83	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
22918158-2	2012	EFV is a known inducer of cytochrome P450 3A4, which converts artemether to dihydroartemisinin (DHA) that is also active and metabolizes longer acting lumefantrine (LR).	efavirenz	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-45
22933296-5	2012	After three doses over 4 days of EFV monotherapy, 103N mutations (AAC and AAT) rapidly emerged and increased in the population to levels of ~20%, indicating that they were present prior to EFV exposure.	efavirenz	33-36	serpin family A member 1	Homo sapiens	74-77
22678819-6	2012	Finally, we demonstrated that FAP48 over-expression was able to influence the capacity of some HIV drugs, Saquinavir and Efavirenz, but not Stavudine, Amprenavir, and Indinavir to inhibit adipocyte formation.	efavirenz	121-130	glomulin, FKBP associated protein	Homo sapiens	30-35
22933296-5	2012	After three doses over 4 days of EFV monotherapy, 103N mutations (AAC and AAT) rapidly emerged and increased in the population to levels of ~20%, indicating that they were present prior to EFV exposure.	efavirenz	33-36	glycine-N-acyltransferase	Homo sapiens	66-69
22309114-8	2012	In addition, adults initiating EFV-based cART at higher baseline CD4(+) cell count values had more favorable outcomes compared to those initiating NVP-based cART.	efavirenz	31-34	CD4 molecule	Homo sapiens	65-68
22050695-3	2012	In this study, we examined in naive HIV-infected patients the in vivo effects of a highly active antiretroviral therapy (HAART) regimen, containing tenofovir-DF/emtricitabine/efavirenz, on PAF metabolism.	efavirenz	175-184	PCNA clamp associated factor	Homo sapiens	189-192
22050695-11	2012	Apart from its classical antiretroviral activities the tenofovir-DF/emtricitabine/efavirenz regimen also exhibited favorable effects on PAF metabolism and therefore may also display beneficial effects in some HIV-related conditions, such as cardiovascular disease (CVD), in which PAF is implicated.	efavirenz	82-91	PCNA clamp associated factor	Homo sapiens	136-139
22050695-11	2012	Apart from its classical antiretroviral activities the tenofovir-DF/emtricitabine/efavirenz regimen also exhibited favorable effects on PAF metabolism and therefore may also display beneficial effects in some HIV-related conditions, such as cardiovascular disease (CVD), in which PAF is implicated.	efavirenz	82-91	PCNA clamp associated factor	Homo sapiens	280-283
21719718-5	2012	The lopinavir/ritonavir dose of 500/125 mg bid administered with efavirenz most closely approximates the pharmacokinetic exposure of lopinavir/ritonavir 400/100 mg bid administered alone.	efavirenz	65-74	BH3 interacting domain death agonist	Homo sapiens	43-46
22398970-8	2012	Efavirenz induced hepatocyte CYP2B6 and CYP3A4 expression, activity, and methadone N-demethylation.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	29-35
22759796-8	2012	Genetic polymorphisms affecting the activity and/or the expression of cytochromes P450 or UGT isozymes and membrane drug transport proteins are highlighted and include such examples as the association of neurotoxicity with efavirenz, nephrotoxicity with tenofovir, hepatotoxicity with nevirapine, and hyperbilirubinemia with indinavir and atazanavir.	efavirenz	223-232	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	90-93
22415932-0	2012	Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1"-hydroxylation in vitro.	efavirenz	20-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-74
22415932-0	2012	Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1"-hydroxylation in vitro.	efavirenz	45-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-74
22415932-3	2012	In vivo data suggested a possible acute activation of CYP3A4-catalyzed midazolam metabolism by efavirenz.	efavirenz	95-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-60
22588604-2	2012	In order to determine the in vivo effects of efavirenz, a CAR activator, the expression of target genes was determined in duodenal biopsies obtained from 12 healthy volunteers before treatment and after 10 days of treatment with efavirenz; concomitant administration of the cholesterol inhibitor ezetimibe produced no significant difference.	efavirenz	45-54	nuclear receptor subfamily 1 group I member 3	Homo sapiens	58-61
22398970-8	2012	Efavirenz induced hepatocyte CYP2B6 and CYP3A4 expression, activity, and methadone N-demethylation.	efavirenz	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
22252501-4	2012	Efavirenz potently inhibited  UGT1A4-mediated trifluoperazine N-glucuronidation and UGT1A9-mediated propofol glucuronidation, with K(i) values of 2.0 and 9.4 muM, respectively.	efavirenz	0-9	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	30-36
22318618-2	2012	We evaluated the effects of multiple doses of efavirenz on omeprazole 5-hydroxylation (CYP2C19) and sulfoxidation (CYP3A).	efavirenz	46-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	87-94
22321026-7	2012	Trials investigating the efficacy of once-daily co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF) demonstrate a high rate of virologic suppression with fewer CNS and psychiatric adverse events compared with co-formulated efavirenz/emtricitabine/tenofovir.	efavirenz	252-261	sex determining region Y	Homo sapiens	124-127
22297387-7	2012	Efavirenz (single dose) slightly increased ezetimibe absorption and markedly decreased exposure to ezetimibe-glucuronide (single dose and multiple dose), which may be explained by inhibition of UGT1A1 and ABCB1 (in vitro data).	efavirenz	0-9	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	194-200
22297387-7	2012	Efavirenz (single dose) slightly increased ezetimibe absorption and markedly decreased exposure to ezetimibe-glucuronide (single dose and multiple dose), which may be explained by inhibition of UGT1A1 and ABCB1 (in vitro data).	efavirenz	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	205-210
22252501-4	2012	Efavirenz potently inhibited  UGT1A4-mediated trifluoperazine N-glucuronidation and UGT1A9-mediated propofol glucuronidation, with K(i) values of 2.0 and 9.4 muM, respectively.	efavirenz	0-9	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	84-90
22252501-4	2012	Efavirenz potently inhibited  UGT1A4-mediated trifluoperazine N-glucuronidation and UGT1A9-mediated propofol glucuronidation, with K(i) values of 2.0 and 9.4 muM, respectively.	efavirenz	0-9	latexin	Homo sapiens	158-161
22252501-6	2012	Efavirenz also moderately inhibited UGT1A1-mediated 17beta-estradiol 3-glucuronidation, with a K(i) value of 40.3 muM, but did not inhibit UGT1A6-mediated 1-naphthol glucuronidation.	efavirenz	0-9	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	36-42
22252501-6	2012	Efavirenz also moderately inhibited UGT1A1-mediated 17beta-estradiol 3-glucuronidation, with a K(i) value of 40.3 muM, but did not inhibit UGT1A6-mediated 1-naphthol glucuronidation.	efavirenz	0-9	latexin	Homo sapiens	114-117
21958719-0	2011	Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes.	efavirenz	0-9	mitogen-activated protein kinase 8	Homo sapiens	57-60
21561322-4	2012	RESULTS: The medications with the highest effects were efavirenz with an ROR of 196 (95% CI, 86 to 447), lamivudine with an ROR of 60.2 (95% CI, 14.25 to 148), the combination abacavir sulfate/lamivudine/zidovudine with an ROR of 59.3, and nelfinavir with and ROR of 50.5, followed by nevirapine, lopinavir/ritonavir, and lamivudine/zidovudine.	efavirenz	55-64	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	73-76
23082557-3	2012	The present study examined the influence of ABCB-1 polymorphisms on plasma nevirapine and efavirenz levels when co-administered with rifampicin in 124 HIV/TB patients who received nevirapine- (400 mg/day) (n = 59) and efavirenz- (600 mg/day) (n = 65) based ART.	efavirenz	90-99	ATP binding cassette subfamily B member 1	Homo sapiens	44-50
21958719-3	2011	In the present study, incubation of primary human hepatocytes with synthetic 8-hydroxyEFV (8-OHEFV), which is the primary metabolite of EFV, resulted in cell death, caspase-3 activation and reactive oxygen species formation.	efavirenz	86-89	caspase 3	Homo sapiens	165-174
21958719-6	2011	Treatment of primary human hepatocytes with EFV and 8-OHEFV also stimulated phosphorylation of c-Jun N-terminal kinase (JNK) as well as phosphorylation of the JNK substrate c-Jun.	efavirenz	44-47	mitogen-activated protein kinase 8	Homo sapiens	95-118
21958719-6	2011	Treatment of primary human hepatocytes with EFV and 8-OHEFV also stimulated phosphorylation of c-Jun N-terminal kinase (JNK) as well as phosphorylation of the JNK substrate c-Jun.	efavirenz	44-47	mitogen-activated protein kinase 8	Homo sapiens	120-123
21958719-6	2011	Treatment of primary human hepatocytes with EFV and 8-OHEFV also stimulated phosphorylation of c-Jun N-terminal kinase (JNK) as well as phosphorylation of the JNK substrate c-Jun.	efavirenz	44-47	mitogen-activated protein kinase 8	Homo sapiens	159-162
21958719-6	2011	Treatment of primary human hepatocytes with EFV and 8-OHEFV also stimulated phosphorylation of c-Jun N-terminal kinase (JNK) as well as phosphorylation of the JNK substrate c-Jun.	efavirenz	44-47	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	95-100
21803024-3	2011	The breast cancer resistant protein (BCRP, ABCG2) is known to be inhibited by EFV in vitro.	efavirenz	78-81	ATP binding cassette subfamily G member 2	Rattus norvegicus	43-48
21803024-4	2011	Since ABCG2 is profusely expressed in the gastrointestinal tract, the aim of the present work was to thoroughly investigate whether the intestinal permeability of EFV is modulated by ABCG2.	efavirenz	163-166	ATP binding cassette subfamily G member 2	Rattus norvegicus	6-11
21803024-4	2011	Since ABCG2 is profusely expressed in the gastrointestinal tract, the aim of the present work was to thoroughly investigate whether the intestinal permeability of EFV is modulated by ABCG2.	efavirenz	163-166	ATP binding cassette subfamily G member 2	Rattus norvegicus	183-188
21803024-7	2011	Since the intestinal permeability of a drug could be associated with its in vivo absorbability, we suggest that the oral absorption of EFV is affected by modifications in the ABCG2 intestinal expression contributing to the intra-individual bioavailability variations.	efavirenz	135-138	ATP binding cassette subfamily G member 2	Rattus norvegicus	175-180
21821736-0	2011	Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.	efavirenz	78-87	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	98-104
21821736-1	2011	There are a number of reports indicating that CYP2B6*6 (c.516G>T and c.785A>G) is responsible for decreased clearance of efavirenz (EFV), although increased disposition of cyclophosphamide (CPA) in individuals with this polymorphism was observed.	efavirenz	138-141	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
21395646-0	2011	In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.	efavirenz	24-33	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	94-100
21301907-1	2011	Mounting evidence thus far indicates that human cytochrome P450 2B6 (CYP2B6), an enzyme expressed at a relatively low level functionally, is primarily responsible for the metabolism of several clinically relevant drugs, including propofol, efavirenz, bupropion, mephobarbital, and the propofol analog 2,6-di-sec-butyl phenol.	efavirenz	240-249	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	48-67
21301907-1	2011	Mounting evidence thus far indicates that human cytochrome P450 2B6 (CYP2B6), an enzyme expressed at a relatively low level functionally, is primarily responsible for the metabolism of several clinically relevant drugs, including propofol, efavirenz, bupropion, mephobarbital, and the propofol analog 2,6-di-sec-butyl phenol.	efavirenz	240-249	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	69-75
21659470-1	2011	In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants.	efavirenz	40-49	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	101-107
21659470-1	2011	In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants.	efavirenz	40-49	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	119-125
21659470-1	2011	In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants.	efavirenz	40-49	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	119-125
21659470-1	2011	In this study, metabolism of bupropion, efavirenz, and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) by CYP2B6 wild type (CYP2B6.1) and six polymorphic variants (CYP2B6.4 to CYP2B6.9) was investigated in a reconstituted system to gain a better understanding of the effects of the mutations on the catalytic properties of these naturally occurring variants.	efavirenz	40-49	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	119-125
21659470-3	2011	The steady-state turnover rates for the hydroxylation of bupropion and efavirenz and the O-deethylation of 7-EFC showed that these mutations significantly alter the catalytic activities of CYP2B6.	efavirenz	71-80	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	189-195
21659470-4	2011	It was found that CYP2B6.6 exhibits 4- and 27-fold increases in the K(m) values for the hydroxylation of bupropion and efavirenz, respectively, and CYP2B6.8 completely loses its ability to metabolize any of the substrates under normal turnover conditions.	efavirenz	119-128	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	18-24
21659470-4	2011	It was found that CYP2B6.6 exhibits 4- and 27-fold increases in the K(m) values for the hydroxylation of bupropion and efavirenz, respectively, and CYP2B6.8 completely loses its ability to metabolize any of the substrates under normal turnover conditions.	efavirenz	119-128	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	148-154
21080015-2	2011	We used the docking method to explore possible binding modes of an entry inhibitor (maraviroc) and non-nucleoside reverse transcriptase inhibitors (delavirdine, efavirenz and etravirine) to cytochrome P450 3A4 (CYP3A4).	efavirenz	161-170	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	190-209
21080015-2	2011	We used the docking method to explore possible binding modes of an entry inhibitor (maraviroc) and non-nucleoside reverse transcriptase inhibitors (delavirdine, efavirenz and etravirine) to cytochrome P450 3A4 (CYP3A4).	efavirenz	161-170	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	211-217
21080015-4	2011	We observed that efavirenz and etravirine induce metabolism of co-administered drugs by binding to a unique position in the active site of CYP3A4.	efavirenz	17-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-145
21395646-8	2011	Increasing the efavirenz dose during concomitant rifampicin was predicted to be most successful in patients over 50 kg regardless of CYP2B6 status.	efavirenz	15-24	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	133-139
21091096-7	2011	Protease inhibitor (PI) usage was similar in both M-IRS categories (43 vs. 38%; p = 0.38) but increased use of efavirenz was seen in M-IRS (47 vs. 36%; p = 0.07) and nevirapine in the non-M-IRS groups (10 vs. 20%; p = 0.05).	efavirenz	111-120	isoleucyl-tRNA synthetase 1	Homo sapiens	135-138
21091096-7	2011	Protease inhibitor (PI) usage was similar in both M-IRS categories (43 vs. 38%; p = 0.38) but increased use of efavirenz was seen in M-IRS (47 vs. 36%; p = 0.07) and nevirapine in the non-M-IRS groups (10 vs. 20%; p = 0.05).	efavirenz	111-120	isoleucyl-tRNA synthetase 1	Homo sapiens	135-138
20699409-6	2010	Cotreatment of avasimibe or efavirenz with 10 muM rifampicin was found to reduce CYP3A activities induced by rifampicin at a lower rate than treatment with rifampicin alone, whereas treatment with phenobarbital and carbamazepine had no effect.	efavirenz	28-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-86
20861742-5	2010	Darunavir, fosamprenavir, lopinavir, nelfinavir, tipranavir, efavirenz, and abacavir increased CYP3A4 and/or CYP2B6 promoter activity, some through constitutive androstane receptor but mainly through PXR.	efavirenz	61-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
20861742-5	2010	Darunavir, fosamprenavir, lopinavir, nelfinavir, tipranavir, efavirenz, and abacavir increased CYP3A4 and/or CYP2B6 promoter activity, some through constitutive androstane receptor but mainly through PXR.	efavirenz	61-70	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	109-115
20861742-5	2010	Darunavir, fosamprenavir, lopinavir, nelfinavir, tipranavir, efavirenz, and abacavir increased CYP3A4 and/or CYP2B6 promoter activity, some through constitutive androstane receptor but mainly through PXR.	efavirenz	61-70	nuclear receptor subfamily 1 group I member 3	Homo sapiens	148-180
20861742-5	2010	Darunavir, fosamprenavir, lopinavir, nelfinavir, tipranavir, efavirenz, and abacavir increased CYP3A4 and/or CYP2B6 promoter activity, some through constitutive androstane receptor but mainly through PXR.	efavirenz	61-70	nuclear receptor subfamily 1 group I member 2	Homo sapiens	200-203
21090588-4	2010	The effect of efavirenz on the solution conformations of p66 and p51 monomers was studied by hydrogen-deuterium exchange mass spectrometry (HXMS) and Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS).	efavirenz	14-23	DNA polymerase delta 3, accessory subunit	Homo sapiens	57-60
21090588-4	2010	The effect of efavirenz on the solution conformations of p66 and p51 monomers was studied by hydrogen-deuterium exchange mass spectrometry (HXMS) and Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS).	efavirenz	14-23	tumor protein p63	Homo sapiens	65-68
21073442-10	2010	In previously differentiated adipocytes, EFV caused a significant reduction in PPARgamma and adiponectin expression, whereas LPV/r did not.	efavirenz	41-44	peroxisome proliferator activated receptor gamma	Homo sapiens	79-88
20660679-2	2010	In vitro data indicate that efavirenz induces several ATP-binding cassette (ABC) transporters, and pharmacogenetic studies found an association between ABCB1(C3435T) and efavirenz exposure and between this polymorphism and improved virological outcomes.	efavirenz	28-37	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	54-74
20660679-2	2010	In vitro data indicate that efavirenz induces several ATP-binding cassette (ABC) transporters, and pharmacogenetic studies found an association between ABCB1(C3435T) and efavirenz exposure and between this polymorphism and improved virological outcomes.	efavirenz	28-37	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	76-79
20660679-2	2010	In vitro data indicate that efavirenz induces several ATP-binding cassette (ABC) transporters, and pharmacogenetic studies found an association between ABCB1(C3435T) and efavirenz exposure and between this polymorphism and improved virological outcomes.	efavirenz	28-37	ATP binding cassette subfamily B member 1	Homo sapiens	152-157
21073442-10	2010	In previously differentiated adipocytes, EFV caused a significant reduction in PPARgamma and adiponectin expression, whereas LPV/r did not.	efavirenz	41-44	adiponectin, C1Q and collagen domain containing	Homo sapiens	93-104
19674747-10	2010	Chemical JNK inhibitor and dominant negative mutant JNK and IkappaBalpha adenoviruses effectively blocked the effects of EFV on HCAECs.	efavirenz	121-124	mitogen-activated protein kinase 8	Homo sapiens	9-12
20090545-0	2010	Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.	efavirenz	45-54	CD4 molecule	Homo sapiens	116-119
20338069-1	2010	BACKGROUND: Cytochrome P450 2B6 (CYP2B6) metabolizes efavirenz and nevirapine, the major core antiretroviral drugs for HIV in Thailand.	efavirenz	53-62	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	12-31
20338069-1	2010	BACKGROUND: Cytochrome P450 2B6 (CYP2B6) metabolizes efavirenz and nevirapine, the major core antiretroviral drugs for HIV in Thailand.	efavirenz	53-62	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	33-39
20408889-6	2010	RESULTS: Efavirenz induced growth in MCF-7 cells with an estimated effective concentration for half-maximal growth (EC(50)) of 15.7 muM.	efavirenz	9-18	latexin	Homo sapiens	132-135
20408889-8	2010	Further, efavirenz binds directly to the ER [inhibitory concentration for half maximal binding (IC(50)) of ~52 muM] at a roughly 1000-fold higher concentration than observed with 17beta-oestradiol.	efavirenz	9-18	latexin	Homo sapiens	111-114
20404738-4	2010	Mean change in baseline CD4 count was 240 and 225 cells per cubic millimeter in the raltegravir and efavirenz groups, respectively [Delta (95% confidence interval) = 15 (-13 to 42)].	efavirenz	100-109	CD4 molecule	Homo sapiens	24-27
20860463-12	2010	CONCLUSION: Our study corroborates previous findings indicating that knowledge of CYP2B6 genetic status should be taken into account for an EFV treatment.	efavirenz	140-143	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	82-88
19674747-10	2010	Chemical JNK inhibitor and dominant negative mutant JNK and IkappaBalpha adenoviruses effectively blocked the effects of EFV on HCAECs.	efavirenz	121-124	mitogen-activated protein kinase 8	Homo sapiens	52-55
19674747-10	2010	Chemical JNK inhibitor and dominant negative mutant JNK and IkappaBalpha adenoviruses effectively blocked the effects of EFV on HCAECs.	efavirenz	121-124	NFKB inhibitor alpha	Homo sapiens	60-72
19702527-4	2009	CYP2B6 can metabolise approximately 8% of clinically used drugs (n > 60), including cyclophosphamide, ifosfamide, tamoxifen, ketamine, artemisinin, nevirapine, efavirenz, bupropion, sibutramine, and propofol.	efavirenz	163-172	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
20002083-4	2009	WHAT THIS STUDY ADDS: * In the present work, we studied the effect of EFV on the activity of PON-1 and showed, for the first time, that EFV-based antiretroviral therapy is associated with a better antioxidant function, i.e. with a higher PON-1 activity.	efavirenz	70-73	paraoxonase 1	Homo sapiens	93-98
20002083-4	2009	WHAT THIS STUDY ADDS: * In the present work, we studied the effect of EFV on the activity of PON-1 and showed, for the first time, that EFV-based antiretroviral therapy is associated with a better antioxidant function, i.e. with a higher PON-1 activity.	efavirenz	136-139	paraoxonase 1	Homo sapiens	93-98
20002083-4	2009	WHAT THIS STUDY ADDS: * In the present work, we studied the effect of EFV on the activity of PON-1 and showed, for the first time, that EFV-based antiretroviral therapy is associated with a better antioxidant function, i.e. with a higher PON-1 activity.	efavirenz	136-139	paraoxonase 1	Homo sapiens	238-243
20002083-10	2009	The influence of treatment with EFV, HDL-c and CD4 cell count on PON-1 activity was analysed.	efavirenz	32-35	paraoxonase 1	Homo sapiens	65-70
20002083-13	2009	CONCLUSIONS: EFV-based antiretroviral regimens are associated with HDL particles with a better antioxidant function, i.e. with a higher PON-1 activity.	efavirenz	13-16	paraoxonase 1	Homo sapiens	136-141
20386083-2	2010	We studied MRP1 expression and function in healthy volunteers treated with darunavir/ritonavir and efavirenz.	efavirenz	99-108	CD9 molecule	Homo sapiens	11-15
20386083-10	2010	MRP1 efflux function was increased after efavirenz administration (GMR 3.13, 95% CI 2.73-3.59; P<0.001) and darunavir/ritonavir plus efavirenz coadministration (GMR 4.35, 95% CI 3.35-5.68; P<0.001), but not after darunavir/ritonavir administration (GMR 1.06, 95% CI 0.80-1.42; P=0.42).	efavirenz	41-50	CD9 molecule	Homo sapiens	0-4
20201776-3	2010	Since EFV is most commonly used with ATV and RTV, the known CYP inhibitors, we evaluated the effects of combinations of these agents on the CYP3A4 induction by EFV.	efavirenz	160-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146
20201776-4	2010	We determined the induction of CYP3A4 by EFV, RTV, ATV, EFV+RTV, EFV+ATV, EFV+RTV+ATV and rifampicin (RIF) employing primary human hepatocytes from 3 donors.	efavirenz	41-44	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
20201776-4	2010	We determined the induction of CYP3A4 by EFV, RTV, ATV, EFV+RTV, EFV+ATV, EFV+RTV+ATV and rifampicin (RIF) employing primary human hepatocytes from 3 donors.	efavirenz	56-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
20201776-4	2010	We determined the induction of CYP3A4 by EFV, RTV, ATV, EFV+RTV, EFV+ATV, EFV+RTV+ATV and rifampicin (RIF) employing primary human hepatocytes from 3 donors.	efavirenz	56-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
20201776-4	2010	We determined the induction of CYP3A4 by EFV, RTV, ATV, EFV+RTV, EFV+ATV, EFV+RTV+ATV and rifampicin (RIF) employing primary human hepatocytes from 3 donors.	efavirenz	56-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
20201776-6	2010	CYP3A4 activity (testosterone-6beta-hydroxylation) was induced by EFV (3 fold) and RIF (4 fold), but was significantly suppressed in the presence of RTV and ATV.	efavirenz	66-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
20201776-8	2010	hPXR activation data in LS180 cells were consistent with the induction of transcripts and the estimated EC(50) values were 0.87 microM, 0.44 microM and 3.7 microM for RIF, RTV and EFV, respectively.	efavirenz	180-183	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-4
20201776-10	2010	This observation corresponds to the clinical observations of attenuated CYP3A4 induction by EFV induction in the presence of RTV and other protease inhibitors (PIs).	efavirenz	92-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
20001610-6	2010	The CYP2B6 G to T polymorphism at position 516 is shown to be associated with elevated plasma concentrations and an increase in neurotoxicity of EFV, while the wild-type genotype has been associated with sub-therapeutic concentrations of EFV, potentially leading to the development of viral resistance.	efavirenz	145-148	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	4-10
20001610-6	2010	The CYP2B6 G to T polymorphism at position 516 is shown to be associated with elevated plasma concentrations and an increase in neurotoxicity of EFV, while the wild-type genotype has been associated with sub-therapeutic concentrations of EFV, potentially leading to the development of viral resistance.	efavirenz	238-241	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	4-10
19487252-2	2009	The glucuronidation of EFV was screened with UGT1A and UGT2B enzymes expressed in a heterologous system, and UGT2B7 was shown to be the only reactive enzyme.	efavirenz	23-26	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	45-50
19487252-1	2009	The non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) is directly conjugated by the UDP-glucuronosyltransferase (UGT) pathway to form EFV-N-glucuronide (EFV-G), but the enzyme(s) involved has not yet been identified.	efavirenz	51-60	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	97-124
19487252-1	2009	The non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) is directly conjugated by the UDP-glucuronosyltransferase (UGT) pathway to form EFV-N-glucuronide (EFV-G), but the enzyme(s) involved has not yet been identified.	efavirenz	51-60	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	126-129
19487252-1	2009	The non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) is directly conjugated by the UDP-glucuronosyltransferase (UGT) pathway to form EFV-N-glucuronide (EFV-G), but the enzyme(s) involved has not yet been identified.	efavirenz	62-65	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	97-124
19487252-1	2009	The non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) is directly conjugated by the UDP-glucuronosyltransferase (UGT) pathway to form EFV-N-glucuronide (EFV-G), but the enzyme(s) involved has not yet been identified.	efavirenz	62-65	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	126-129
19487252-2	2009	The glucuronidation of EFV was screened with UGT1A and UGT2B enzymes expressed in a heterologous system, and UGT2B7 was shown to be the only reactive enzyme.	efavirenz	23-26	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	109-115
19487252-4	2009	Because 3"-azido-3"-deoxythymidine (AZT), one of the most current nucleotide reverse transcriptase inhibitors prescribed in combination with EFV, is also conjugated by UGT2B7, the potential metabolic interaction between EFV and AZT has been studied using human liver microsomes.	efavirenz	141-144	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	168-174
19487252-4	2009	Because 3"-azido-3"-deoxythymidine (AZT), one of the most current nucleotide reverse transcriptase inhibitors prescribed in combination with EFV, is also conjugated by UGT2B7, the potential metabolic interaction between EFV and AZT has been studied using human liver microsomes.	efavirenz	220-223	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	168-174
19531981-1	2009	Cytochrome P450 2B6 (CYP2B6) is the main metabolizing pathway for efavirenz (EFV), the prescription of which is associated with neurologic side effects.	efavirenz	66-75	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-19
19531981-1	2009	Cytochrome P450 2B6 (CYP2B6) is the main metabolizing pathway for efavirenz (EFV), the prescription of which is associated with neurologic side effects.	efavirenz	66-75	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	21-27
19531981-1	2009	Cytochrome P450 2B6 (CYP2B6) is the main metabolizing pathway for efavirenz (EFV), the prescription of which is associated with neurologic side effects.	efavirenz	77-80	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-19
19531981-1	2009	Cytochrome P450 2B6 (CYP2B6) is the main metabolizing pathway for efavirenz (EFV), the prescription of which is associated with neurologic side effects.	efavirenz	77-80	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	21-27
18990393-5	2009	RESULTS: LDLr-/- and hA-I transgenic mice treated with nevirapine and efavirenz had a significant increase in HDL-C level (up to 23% in hA-I transgenic) at 4 weeks.	efavirenz	70-79	low density lipoprotein receptor	Mus musculus	9-13
18990393-5	2009	RESULTS: LDLr-/- and hA-I transgenic mice treated with nevirapine and efavirenz had a significant increase in HDL-C level (up to 23% in hA-I transgenic) at 4 weeks.	efavirenz	70-79	serine peptidase inhibitor, Kunitz type 1	Homo sapiens	21-25
18990393-5	2009	RESULTS: LDLr-/- and hA-I transgenic mice treated with nevirapine and efavirenz had a significant increase in HDL-C level (up to 23% in hA-I transgenic) at 4 weeks.	efavirenz	70-79	serine peptidase inhibitor, Kunitz type 1	Homo sapiens	136-140
18990393-9	2009	Incubation of plasma from hA-I transgenic mice treated for 4 weeks with [(3)H]-cholesterol-labeled macrophages revealed increased cholesterol efflux to plasma from mice treated with efavirenz and nevirapine.	efavirenz	182-191	serine peptidase inhibitor, Kunitz type 1	Homo sapiens	26-30
23675126-4	2009	Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6) and the metabolic effects of EFV have been described previously.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	44-63
23675126-4	2009	Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6) and the metabolic effects of EFV have been described previously.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	65-71
23675126-4	2009	Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6) and the metabolic effects of EFV have been described previously.	efavirenz	11-14	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	44-63
23675126-4	2009	Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6) and the metabolic effects of EFV have been described previously.	efavirenz	11-14	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	65-71
23675126-4	2009	Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6) and the metabolic effects of EFV have been described previously.	efavirenz	102-105	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	65-71
19239339-1	2009	BACKGROUND: Polymorphisms in CYP2B6 affect the steady-state plasma concentrations of nevirapine and efavirenz.	efavirenz	100-109	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	29-35
19286836-9	2009	The vitamin D(3) 25-hydroxylase activity in fibroblasts was suppressed by both calcitriol and efavirenz.	efavirenz	94-103	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	4-31
19371316-10	2009	Multiple linear regression analysis indicated that the CYP2B6 c.516G-->T polymorphism and CYP2A6 slow-metabolizing variants accounted for as much as 36 and 12% of the total variance in efavirenz concentrations, respectively.	efavirenz	188-197	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	55-61
19371316-10	2009	Multiple linear regression analysis indicated that the CYP2B6 c.516G-->T polymorphism and CYP2A6 slow-metabolizing variants accounted for as much as 36 and 12% of the total variance in efavirenz concentrations, respectively.	efavirenz	188-197	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	93-99
19238117-4	2009	We hypothesize that genetic variability in this gene may contribute to the particularly high, unexplained variability in EFV exposure in individuals with limited CYP2B6 function.	efavirenz	121-124	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	162-168
19866531-4	2009	His EFV plasma concentrations were always above normal and he was homozygous for a deficient function-allele of CYP2D6; for this reason, his EFV dose was reduced to 400mg=d.	efavirenz	4-7	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	112-118
19866531-4	2009	His EFV plasma concentrations were always above normal and he was homozygous for a deficient function-allele of CYP2D6; for this reason, his EFV dose was reduced to 400mg=d.	efavirenz	141-144	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	112-118
19239339-10	2009	The composite CYP2B6 516/983 genotype was significantly associated with plasma drug exposure and clearance for efavirenz but not nevirapine.	efavirenz	111-120	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	14-20
19018877-3	2009	METHODS: Insulin resistance was assessed at 96 weeks of treatment with nonnucleoside reverse transcriptase inhibitor (NNRTI)-based HAART (nevirapine or efavirenz with stavudine and lamivudine) among children in Chiang Mai, Thailand.	efavirenz	152-161	insulin	Homo sapiens	9-16
19234366-1	2009	Efavirenz, an important component of human immunodeficiency virus 1 (HIV-1) therapy, causes substantial drug interactions as an inducer of cytochromes and the transporter ABCB1.	efavirenz	0-9	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	171-176
18784455-12	2008	As HIV-infected hemodialysis patients are disproportionately black, the increased frequency of the CYP2B6 516G>T polymorphism may lead to higher EFV levels.	efavirenz	148-151	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	99-105
19474465-2	2009	Single nucleotide polymorphisms of the hepatic cytochrome P450 isoenzyme 2B6 (CYP2B6) gene have been associated with high interindividual variations in EFV plasma concentrations.	efavirenz	152-155	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	47-76
19474465-2	2009	Single nucleotide polymorphisms of the hepatic cytochrome P450 isoenzyme 2B6 (CYP2B6) gene have been associated with high interindividual variations in EFV plasma concentrations.	efavirenz	152-155	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	78-84
19474465-3	2009	Our objective was to determine the adequacy of EFV dosing and explore the influence of CYP2B6-516G>T polymorphisms on EFV plasma concentrations in Thai HIV-infected children.	efavirenz	121-124	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	87-93
19474465-15	2009	CYP2B6-516G>T polymorphisms significantly affect the drug metabolism of EFV in children.	efavirenz	75-78	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
18989234-0	2008	Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	18-24
18989234-9	2008	CONCLUSIONS: Our results confirm that efavirenz induces CYP2B6 enzyme activity in vivo, as demonstrated by an increase in bupropion hydroxylation after 2 weeks of efavirenz administration.	efavirenz	38-47	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	56-62
18989234-9	2008	CONCLUSIONS: Our results confirm that efavirenz induces CYP2B6 enzyme activity in vivo, as demonstrated by an increase in bupropion hydroxylation after 2 weeks of efavirenz administration.	efavirenz	163-172	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	56-62
19834271-10	2009	EFV, ritonavir (RTV) and nelfinavir (NFV) inhibited the expression of adiponectin mRNA in mature 3T3-L1 and to a greater extent in pre-mature 3T3-L1.	efavirenz	0-3	adiponectin, C1Q and collagen domain containing	Homo sapiens	70-81
18640157-5	2008	Treatment with efavirenz resulted in an increased MAPPIT signal, with an EC50 value of 64nM for the p66/p51 interaction, and allowed detection of the p51/p51 homodimerization, confirming the context-dependent asymmetric contribution of both subunits.	efavirenz	15-24	DNA polymerase delta 3, accessory subunit	Homo sapiens	100-103
18640157-5	2008	Treatment with efavirenz resulted in an increased MAPPIT signal, with an EC50 value of 64nM for the p66/p51 interaction, and allowed detection of the p51/p51 homodimerization, confirming the context-dependent asymmetric contribution of both subunits.	efavirenz	15-24	tumor protein p63	Homo sapiens	104-107
18640157-5	2008	Treatment with efavirenz resulted in an increased MAPPIT signal, with an EC50 value of 64nM for the p66/p51 interaction, and allowed detection of the p51/p51 homodimerization, confirming the context-dependent asymmetric contribution of both subunits.	efavirenz	15-24	tumor protein p63	Homo sapiens	150-153
18640157-5	2008	Treatment with efavirenz resulted in an increased MAPPIT signal, with an EC50 value of 64nM for the p66/p51 interaction, and allowed detection of the p51/p51 homodimerization, confirming the context-dependent asymmetric contribution of both subunits.	efavirenz	15-24	tumor protein p63	Homo sapiens	150-153
18781911-5	2008	These individual differences may result in variable systemic exposure to drugs metabolized by CYP2B6, including the antineoplastics cyclophosphamide and ifosfamide, the antiretrovirals nevirapine and efavirenz, the anesthetics propofol and ketamine, the synthetic opioid methadone, and the anti-Parkinsonian selegiline.	efavirenz	200-209	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	94-100
18620493-5	2008	Among the drugs tested, several inhibited PAF-induced platelet aggregation in a concentration-depended manner, with tenofovir, efavirenz, and ritonavir exhibiting the higher inhibitory effect.	efavirenz	127-136	PCNA clamp associated factor	Homo sapiens	42-45
18620493-8	2008	In addition, in naive patients treated with one of the most potent anti-PAF HAART regimens (efavirenz/emtricitabine/tenofovir-DF) for a period of 1 month, a significant reduction of the specific activity of PAF-CPT of washed human leukocytes of these patients was also observed, compared with its levels before the HAART treatment.	efavirenz	92-101	PCNA clamp associated factor	Homo sapiens	72-75
18620493-8	2008	In addition, in naive patients treated with one of the most potent anti-PAF HAART regimens (efavirenz/emtricitabine/tenofovir-DF) for a period of 1 month, a significant reduction of the specific activity of PAF-CPT of washed human leukocytes of these patients was also observed, compared with its levels before the HAART treatment.	efavirenz	92-101	PCNA clamp associated factor	Homo sapiens	207-210
18458892-3	2008	Efavirenz is an inducer of CYP3A, whereas the ritonavir-boosted regimens are net inhibitors of CYP3A.	efavirenz	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-32
18458892-7	2008	CONCLUSION: Changes in plasma 4beta-hydroxycholesterol following the initiation of efavirenz- or atazanavir/ritonavir-based antiretroviral therapy reflected the respective net increase and decrease of CYP3A activity of these regimens.	efavirenz	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	201-206
18667933-6	2008	Most EFV patients (92%) were already on EFV before starting IFN (mean 26 months).	efavirenz	5-8	interferon alpha 1	Homo sapiens	60-63
18728241-1	2008	The goal of this study was to determine the effect of CYP2B6 genetic variation on the steady-state pharmacokinetics of efavirenz (600 mg/d) in TB/HIV co-infected patients receiving concomitant rifampin, a potent CYP inducer.	efavirenz	119-128	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	54-60
18728241-1	2008	The goal of this study was to determine the effect of CYP2B6 genetic variation on the steady-state pharmacokinetics of efavirenz (600 mg/d) in TB/HIV co-infected patients receiving concomitant rifampin, a potent CYP inducer.	efavirenz	119-128	peptidylprolyl isomerase G	Homo sapiens	54-57
18351578-7	2008	Indeed, renal carcinoma cells exposed to efavirenz induced a CD8(+)CCR7-CD45RA(-) effector memory T-cell phenotype, whereas untreated RCC cells induced a CD8(+)CCR7(+)CD45RA(-) central memory T-cell phenotype.	efavirenz	41-50	CD8a molecule	Homo sapiens	61-64
18351578-7	2008	Indeed, renal carcinoma cells exposed to efavirenz induced a CD8(+)CCR7-CD45RA(-) effector memory T-cell phenotype, whereas untreated RCC cells induced a CD8(+)CCR7(+)CD45RA(-) central memory T-cell phenotype.	efavirenz	41-50	CD8a molecule	Homo sapiens	154-157
18332078-8	2008	CYP3A4 and CYP2B6 induction in Fa2N-4 cells were also low for phenytoin, phenobarbital, and efavirenz, which are dual activators of PXR/CAR.	efavirenz	92-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
19338072-12	2008	In summary, TDF is a widely used drug in clinical practice due to its excellent combination of effectiveness, durability and tolerability, in addition to its ease of administration in a single daily dose, whether in its individual formation (Viread), or associated with FTC (Truvada), or with FTC and efavirenz (Atripla).	efavirenz	301-310	sex determining region Y	Homo sapiens	12-15
18332078-8	2008	CYP3A4 and CYP2B6 induction in Fa2N-4 cells were also low for phenytoin, phenobarbital, and efavirenz, which are dual activators of PXR/CAR.	efavirenz	92-101	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	11-17
18332078-8	2008	CYP3A4 and CYP2B6 induction in Fa2N-4 cells were also low for phenytoin, phenobarbital, and efavirenz, which are dual activators of PXR/CAR.	efavirenz	92-101	nuclear receptor subfamily 1 group I member 2	Homo sapiens	132-135
18332078-8	2008	CYP3A4 and CYP2B6 induction in Fa2N-4 cells were also low for phenytoin, phenobarbital, and efavirenz, which are dual activators of PXR/CAR.	efavirenz	92-101	nuclear receptor subfamily 1 group I member 3	Homo sapiens	136-139
18057928-9	2008	Pharmacokinetic parameter estimates indicate that a dose reduction to 400 mg efavirenz per day is possible in patients homozygous for the CYP2B6*6 genotype without compromising therapeutic efficacy.	efavirenz	77-86	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	138-144
18333864-28	2008	CONCLUSION: As expected with a CYP3A4 substrate, maraviroc exposure (C(max) and AUC(12)) was significantly reduced by the known CYP3A4 inducers, rifampicin and EFV, by approximately 70% and 50%, respectively.	efavirenz	160-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
18333864-28	2008	CONCLUSION: As expected with a CYP3A4 substrate, maraviroc exposure (C(max) and AUC(12)) was significantly reduced by the known CYP3A4 inducers, rifampicin and EFV, by approximately 70% and 50%, respectively.	efavirenz	160-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-134
17918089-8	2007	All EFV-treated CYP2B6 *6/*6 and *6/*26 carriers had extremely high plasma EFV concentrations (>6000 ng/mL) while receiving the standard dosage.	efavirenz	4-7	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
18419537-0	2008	Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.	efavirenz	0-9	CD4 molecule	Homo sapiens	103-106
18171905-1	2008	CYP2B6 is a polymorphic human drug metabolizing cytochrome P450 with clinical relevance for several drug substrates including cyclophosphamide, bupropion, and efavirenz.	efavirenz	159-168	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
18025525-8	2008	The 200 mg bid voriconazole increased the steady-state mean AUC0-24 and Cmax of efavirenz by 43% (90% CI, 36%-51%) and 37% (90% CI, 29%-46%), respectively.	efavirenz	80-89	BH3 interacting domain death agonist	Homo sapiens	11-14
18097230-6	2008	Median CD4 cell counts increased above respective baselines by 292 cells/mul (efavirenz, zidovudine, lamivudine and indinavir, zidovudine, lamivudine) and 300 cells/mul (efavirenz plus indinavir).	efavirenz	78-87	CD4 molecule	Homo sapiens	7-10
18097230-6	2008	Median CD4 cell counts increased above respective baselines by 292 cells/mul (efavirenz, zidovudine, lamivudine and indinavir, zidovudine, lamivudine) and 300 cells/mul (efavirenz plus indinavir).	efavirenz	170-179	CD4 molecule	Homo sapiens	7-10
18783297-9	2008	Using this equation, the ICCYP3A4 was calculated for seven inducers (bosentan, carbamazepine, efavirenz, phenytoin, pioglitazone, rifampicin [rifampin], and St John"s wort [hypericum]) on the basis of the reduction in the AUC of a coadministered standard substrate of CYP3A4, such as simvastatin, in ten DDI studies.	efavirenz	94-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
17918089-1	2007	BACKGROUND: Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6), and high plasma concentrations of the drug are associated with a G-->T polymorphism at position 516 (516G-->T) of CYP2B6 and frequent central nervous system (CNS)-related side effects.	efavirenz	12-21	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	56-75
17918089-1	2007	BACKGROUND: Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6), and high plasma concentrations of the drug are associated with a G-->T polymorphism at position 516 (516G-->T) of CYP2B6 and frequent central nervous system (CNS)-related side effects.	efavirenz	12-21	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	77-83
17918089-1	2007	BACKGROUND: Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6), and high plasma concentrations of the drug are associated with a G-->T polymorphism at position 516 (516G-->T) of CYP2B6 and frequent central nervous system (CNS)-related side effects.	efavirenz	12-21	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	206-212
17918089-1	2007	BACKGROUND: Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6), and high plasma concentrations of the drug are associated with a G-->T polymorphism at position 516 (516G-->T) of CYP2B6 and frequent central nervous system (CNS)-related side effects.	efavirenz	23-26	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	56-75
17918089-1	2007	BACKGROUND: Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6), and high plasma concentrations of the drug are associated with a G-->T polymorphism at position 516 (516G-->T) of CYP2B6 and frequent central nervous system (CNS)-related side effects.	efavirenz	23-26	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	77-83
17918089-1	2007	BACKGROUND: Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6), and high plasma concentrations of the drug are associated with a G-->T polymorphism at position 516 (516G-->T) of CYP2B6 and frequent central nervous system (CNS)-related side effects.	efavirenz	23-26	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	206-212
17918089-4	2007	EFV dose was reduced in CYP2B6 516G-->T carriers who had high plasma EFV concentrations while receiving the standard dosage (600 mg).	efavirenz	0-3	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	24-30
17918089-8	2007	All EFV-treated CYP2B6 *6/*6 and *6/*26 carriers had extremely high plasma EFV concentrations (>6000 ng/mL) while receiving the standard dosage.	efavirenz	75-78	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
17918089-10	2007	EFV-containing treatment was initiated at 400 mg in 4 CYP2B6 *6/*6 carriers and one *6/*26 carrier.	efavirenz	0-3	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	54-60
17918089-13	2007	CONCLUSIONS: Genotype-based EFV dose reduction is feasible in CYP2B6 *6/*6 and *6/*26 carriers, which can reduce EFV-associated CNS symptoms.	efavirenz	28-31	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	62-68
17918089-13	2007	CONCLUSIONS: Genotype-based EFV dose reduction is feasible in CYP2B6 *6/*6 and *6/*26 carriers, which can reduce EFV-associated CNS symptoms.	efavirenz	113-116	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	62-68
17713424-9	2007	Some cohort studies and randomized clinical trials support the use of efavirenz-based antiretroviral therapy for the treatment of advanced HIV-1-infected patients; however, recent randomized controlled data suggest, in a moderately advanced HIV population, a better CD4 cell recovery for lopinavir-ritonavir than for efavirenz-treated patients, but a greater virological suppression in the efavirenz arm.	efavirenz	70-79	CD4 molecule	Homo sapiens	266-269
17235330-1	2007	To assess the association of CYP2B6 allelic diversity with efavirenz (EFV) pharmacokinetics, we performed extensive genotyping of 15 relevant single nucleotide polymorphism in 169 study participants, and full resequencing of CYP2B6 in individuals with abnormal EFV plasma levels.	efavirenz	59-68	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	29-35
17667341-7	2007	Women had lower CD4 counts when starting EFV (median [interquartile range [IQR] = 126 [36, 220] cells/mm for women vs. 190 [109, 268] cells/mm for men; P = 0.0003).	efavirenz	41-44	CD4 molecule	Homo sapiens	16-19
17361129-6	2007	Considering drugs likely to be coadministered with AQ, the antiretroviral drugs efavirenz, saquinavir, lopinavir, and tipranavir were potent CYP2C8 inhibitors at clinically relevant concentrations.	efavirenz	80-89	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	141-147
17686225-0	2007	Efavirenz-induced neurological symptoms in rare homozygote CYP2B6 *2/*2 (C64T).	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	59-65
17686225-3	2007	For example, CYP2B6 *6 (G516T and A785G) and *7 (G516T, A785G and C1459T) prolonged the EFV half-life despite discontinuation of EFV.	efavirenz	88-91	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	13-19
17683706-0	2007	[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].	efavirenz	78-87	insulin	Homo sapiens	1-8
17683706-7	2007	Insulin resistance was found in 5 (10.6%) patients, 4 among those receiving lopinavir/ritonavir, one among those treated with efavirenz and none among subjects receiving atazanavir (p = 0.065).	efavirenz	126-135	insulin	Homo sapiens	0-7
17653450-8	2007	The mean CD4 cell count increase after a 12-month period was also greater in the efavirenz group (195 x 10(6) cells/L) than in the nelfinavir group (119 x 10(6) cells/L; P = 0.002).	efavirenz	81-90	CD4 molecule	Homo sapiens	9-12
17356468-1	2007	BACKGROUND: The CYP2B6-G516T polymorphism has been shown to alter plasma efavirenz (EFV) concentrations in adults.	efavirenz	84-87	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
17235330-1	2007	To assess the association of CYP2B6 allelic diversity with efavirenz (EFV) pharmacokinetics, we performed extensive genotyping of 15 relevant single nucleotide polymorphism in 169 study participants, and full resequencing of CYP2B6 in individuals with abnormal EFV plasma levels.	efavirenz	70-73	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	29-35
17045554-7	2007	Several studies on efavirenz, a commonly used antiretroviral drug, have reported higher plasma exposure and early side effects with the homozygous variant of the hepatic cytochrome P450 enzyme CYP2B6 G516T polymorphism, which are more frequently found in African-American subjects.	efavirenz	19-28	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	193-199
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	efavirenz	247-256	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	12-18
17202245-6	2007	RESULTS: According to the IC(50) estimation, the rank order for BCRP inhibition was lopinavir > nelfinavir > delavirdine > efavirenz > saquinavir > atazanavir > amprenavir > abacavir.	efavirenz	132-141	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	64-68
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	efavirenz	247-256	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	56-71
17082249-1	2007	BACKGROUND: CYP2B6 is a highly variable and polymorphic cytochrome P450 (CYP) enzyme involved in the biotransformation of an increasing number of drugs, including cyclophosphamide, bupropion, and the nonnucleosidic reverse transcriptase inhibitor efavirenz.	efavirenz	247-256	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-15
17162316-15	2006	CONCLUSION: In this pilot study of patients suppressed on abacavir/lamivudine/zidovudine bid plus EFV, 94% of participants switching to abacavir/lamivudine/zidovudine qd plus EFV maintained virologic suppression, compared to 89% of participants continuing abacavir/lamivudine/zidovudine bid plus EFV.	efavirenz	98-101	BH3 interacting domain death agonist	Homo sapiens	287-290
17539249-12	2007	Serum TC and LDL-c levels were also significantly higher in subjects taking efavirenz.	efavirenz	76-85	component of oligomeric golgi complex 2	Homo sapiens	13-18
17101742-1	2006	Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of drugs such as bupropion, efavirenz, propofol, and selegiline, among others.	efavirenz	87-96	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-19
17101742-1	2006	Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of drugs such as bupropion, efavirenz, propofol, and selegiline, among others.	efavirenz	87-96	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	21-27
17047492-10	2006	Among 155 participants who received efavirenz without nelfinavir, virologic failure was associated with a two-locus interaction between ABCB1 2677G>T and CYP2B6 516G>T (65% accuracy, P<0.001).	efavirenz	36-45	ATP binding cassette subfamily B member 1	Homo sapiens	136-141
17047492-10	2006	Among 155 participants who received efavirenz without nelfinavir, virologic failure was associated with a two-locus interaction between ABCB1 2677G>T and CYP2B6 516G>T (65% accuracy, P<0.001).	efavirenz	36-45	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	157-163
17057609-7	2006	The TDF + FTC + EFV group demonstrated a significantly greater increase in CD4 count (270 vs. 237 cells/mm; P = 0.036).	efavirenz	16-19	CD4 molecule	Homo sapiens	75-78
17334006-8	2006	In the random effects model, there was an increase of 40.97 (p < 0.05) units of CD4 cell counts with an unit increase in time in the NVP arm as against a 44.75 (p < 0.05) units of increase in CD4 cell counts in the EFV group with a unit increase in time, which is significant for both groups.	efavirenz	221-224	CD4 molecule	Homo sapiens	83-86
17100373-14	2006	CONCLUSION: Initiation of EFV-based HAART regimen in HIV-infected patients at CD4 < 100 and > or = 100 cells/ mm3 gains similar immunological and virological response.	efavirenz	26-29	CD4 molecule	Homo sapiens	78-81
17009933-16	2006	Pivotal study 934 evidenced superior efficacy of the combination TDF/FTC/efavirenz (EFV) versus zidovudine/FTC/EFV.	efavirenz	84-87	sex determining region Y	Homo sapiens	65-68
16720753-8	2006	[(3)H]Taurocholate transport by recombinant NTCP and Ntcp was inhibited by ritonavir (IC(50) = 2.1 and 6.4 microM in human and rat, respectively), saquinavir (IC(50) = 6.7 and 20 microM, respectively), and efavirenz (IC(50) = 43 and 97 microM, respectively).	efavirenz	206-215	solute carrier family 10 member 1	Rattus norvegicus	44-48
16720753-8	2006	[(3)H]Taurocholate transport by recombinant NTCP and Ntcp was inhibited by ritonavir (IC(50) = 2.1 and 6.4 microM in human and rat, respectively), saquinavir (IC(50) = 6.7 and 20 microM, respectively), and efavirenz (IC(50) = 43 and 97 microM, respectively).	efavirenz	206-215	solute carrier family 10 member 1	Rattus norvegicus	53-57
16906281-10	2006	Urinary NO3 excretion was significantly lower in IDV-treated patients (809 +/- 181 microM NO3-/mg creatinine) than in efavirenz-treated patients (2247 +/- 648 microM NO3-/mg creatinine, P < 0.01).	efavirenz	118-127	NBL1, DAN family BMP antagonist	Homo sapiens	8-11
16779703-2	2006	METHODS: The uptake of EFV was measured in whole brains of rat and mdr1a-/- and mdr1a+/+ mice, and in GPNT cells (rat brain endothelial cell line) with and without P-gp inhibitors (PSC833, S9788, Quinidine).	efavirenz	23-26	ATP binding cassette subfamily B member 1A	Rattus norvegicus	67-72
16779703-2	2006	METHODS: The uptake of EFV was measured in whole brains of rat and mdr1a-/- and mdr1a+/+ mice, and in GPNT cells (rat brain endothelial cell line) with and without P-gp inhibitors (PSC833, S9788, Quinidine).	efavirenz	23-26	ATP binding cassette subfamily B member 1A	Rattus norvegicus	80-85
16779703-3	2006	The effect of a single dose or multiple doses of EFV on the P-gp functionality was evaluated in vivo and in vitro by measuring the brain and cell uptake of digoxin, completed by the analysis of the P-gp expression at the rat BBB after repeated administrations of EFV.	efavirenz	49-52	phosphoglycolate phosphatase	Rattus norvegicus	60-64
16779703-3	2006	The effect of a single dose or multiple doses of EFV on the P-gp functionality was evaluated in vivo and in vitro by measuring the brain and cell uptake of digoxin, completed by the analysis of the P-gp expression at the rat BBB after repeated administrations of EFV.	efavirenz	49-52	phosphoglycolate phosphatase	Rattus norvegicus	198-202
16267764-1	2005	BACKGROUND: Efavirenz and nelfinavir are metabolized by cytochrome P-450 (CYP) 2B6 and CYP2C19, respectively, with some involvement by CYP3A.	efavirenz	12-21	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	56-82
16779703-10	2006	On the other hand, EFV did not induce P-gp, allowing to sustain the brain accumulation of associated P-gp substrates such as protease inhibitors.	efavirenz	19-22	phosphoglycolate phosphatase	Rattus norvegicus	101-105
16495778-1	2006	The non-nucleoside reverse transcriptase inhibitor efavirenz is mainly metabolised by the polymorphic cytochrome P450 enzyme CYP2B6.	efavirenz	51-60	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	125-131
16495778-2	2006	Genomic DNA from four subjects in a group of 51 patients being treated with efavirenz and having surprisingly high plasma concentrations were screened by direct sequencing for mutations in the CYP2B6 gene.	efavirenz	76-85	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	193-199
16495778-9	2006	The steady-state level of efavirenz was significantly higher in the five carriers of CYP2B6*16, being of African origin, compared to the other patients.	efavirenz	26-35	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	85-91
16495778-10	2006	Higher efavirenz concentrations were also seen in carriers of 516G>T (CYP2B6*6 and CYP2B6*9).	efavirenz	7-16	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	70-76
16495778-10	2006	Higher efavirenz concentrations were also seen in carriers of 516G>T (CYP2B6*6 and CYP2B6*9).	efavirenz	7-16	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	83-89
16495778-11	2006	In conclusion, a novel CYP2B6*16 allele causing less expression of the corresponding enzyme was identified and found to influence the metabolism of efavirenz in vivo, a finding that is of potential impact for anti-HIV therapy in black populations.	efavirenz	148-157	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	23-29
16392089-11	2006	CONCLUSIONS: The CYP2B6 position 516 TT genotype or a prolonged measured elimination half-life may predict increased risk of developing drug resistance among patients who discontinue efavirenz-containing regimens.	efavirenz	183-192	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	17-23
16267764-1	2005	BACKGROUND: Efavirenz and nelfinavir are metabolized by cytochrome P-450 (CYP) 2B6 and CYP2C19, respectively, with some involvement by CYP3A.	efavirenz	12-21	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	87-94
16267764-1	2005	BACKGROUND: Efavirenz and nelfinavir are metabolized by cytochrome P-450 (CYP) 2B6 and CYP2C19, respectively, with some involvement by CYP3A.	efavirenz	12-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-140
16267764-9	2005	Plasma exposure to efavirenz and nelfinavir in each population was significantly associated with the polymorphisms CYP2B6 516G-->T and CYP2C19 681G-->A, respectively.	efavirenz	19-28	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	115-121
16267764-9	2005	Plasma exposure to efavirenz and nelfinavir in each population was significantly associated with the polymorphisms CYP2B6 516G-->T and CYP2C19 681G-->A, respectively.	efavirenz	19-28	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	138-145
16452064-3	2005	RESULTS: The two study groups were comparable, except for the lower baseline CD4+ count found in the EFV group.	efavirenz	101-104	CD4 molecule	Homo sapiens	77-80
16124934-4	2005	METHODS: (i) The effect of EFV on rat intestinal P-gp function was studied on everted gut sacs and in situ intestinal perfusion.	efavirenz	27-30	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	49-53
15769884-1	2005	The polymorphic human cytochrome P450 (P450) 2B6 is primarily responsible for the metabolism of several clinically relevant drugs including bupropion, cyclophosphamide, propofol, and efavirenz.	efavirenz	183-192	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	22-48
15980690-2	2005	EFV is a mixed inducer/inhibitor of cytochrome P450 (CYP) 3A4 isozyme and may interact with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that are primarily metabolized via CYP3A4.	efavirenz	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-61
15980690-2	2005	EFV is a mixed inducer/inhibitor of cytochrome P450 (CYP) 3A4 isozyme and may interact with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that are primarily metabolized via CYP3A4.	efavirenz	0-3	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	92-144
15980690-2	2005	EFV is a mixed inducer/inhibitor of cytochrome P450 (CYP) 3A4 isozyme and may interact with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that are primarily metabolized via CYP3A4.	efavirenz	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	191-197
15657782-7	2005	CYP3A activity was lower in the efavirenz + ritonavir group (P = 0.01) and in the ritonavir group (P = 0.04) than in the nelfinavir group, although already strongly inhibited in the latter.	efavirenz	32-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
15718846-0	2005	The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.	efavirenz	4-13	ATP binding cassette subfamily B member 1	Homo sapiens	71-98
15718846-1	2005	Efavirenz treatment has been associated with increases in HDL-cholesterol concentrations, and the circulating levels of the drug have been related to the multidrug resistance gene 1 (MDR-1) C3435T polymorphism.	efavirenz	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	183-188
15657782-11	2005	The inhibition of CYP3A by ritonavir or nelfinavir offsets the inductive effects of efavirenz or nevirapine administered concomitantly.	efavirenz	84-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-23
15657782-9	2005	Efavirenz strongly induces CYP3A activity, while ritonavir almost completely inhibits it.	efavirenz	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-32
15864119-6	2005	RESULTS AND CONCLUSIONS: CYP2B6 516TT was associated with greater plasma and intracellular exposure to EFV, and greater plasma exposure to NVP.	efavirenz	103-106	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	25-31
15563361-7	2004	During days 11-20 (period 2) efavirenz 600 mg q.d.	efavirenz	29-38	period circadian regulator 2	Homo sapiens	19-27
14628297-13	2004	Our data could explain why the plasma concentration ratio of R/S methadone is variable and why drugs that induce CYP2B6 such as nevirapine and efavirenz also induce methadone metabolism, while the CYP3A4 inducer rifabutin has no effect on methadone pharmacokinetics.	efavirenz	143-152	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	113-119
15194512-1	2004	Efavirenz (EFV) is metabolized by cytochrome P450 2B6 (CYP2B6) in the liver.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-53
15194512-1	2004	Efavirenz (EFV) is metabolized by cytochrome P450 2B6 (CYP2B6) in the liver.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	55-61
15194512-1	2004	Efavirenz (EFV) is metabolized by cytochrome P450 2B6 (CYP2B6) in the liver.	efavirenz	11-14	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-53
15194512-1	2004	Efavirenz (EFV) is metabolized by cytochrome P450 2B6 (CYP2B6) in the liver.	efavirenz	11-14	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	55-61
15864119-1	2005	BACKGROUND: Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6).	efavirenz	23-26	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	68-87
15864119-1	2005	BACKGROUND: Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6).	efavirenz	23-26	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	89-95
15496645-4	2004	Employing primary cultures of human hepatocytes, they compared the CYP3A4 inductive effects of efavirenz (1-10 microM) to rifampin (10 microM) and phenobarbital (2 mM).	efavirenz	95-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
15496645-6	2004	The authors observed that efavirenz caused a concentration-dependent CYP3A4 induction and hPXR activation.	efavirenz	26-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
15496645-6	2004	The authors observed that efavirenz caused a concentration-dependent CYP3A4 induction and hPXR activation.	efavirenz	26-35	nuclear receptor subfamily 1 group I member 2	Homo sapiens	90-94
15496645-7	2004	Based on the CYP3A4 activity assay, the average magnitude of induction by efavirenz (5-10 microM) was approximately 3- to 4-fold.	efavirenz	74-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
15167626-1	2004	Efavirenz is a drug subject to extensive metabolism, mainly by the cytochrome P-450 isoenzyme CYP2B6, known to exhibit extensive interindividual variability.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	94-100
15134483-8	2004	Nevirapine and efavirenz, the commonly prescribed non-nucleoside reverse transcriptase inhibitors, can readily enter the CSF, however, it remains to be seen if a transport system is involved in their distribution.	efavirenz	15-24	colony stimulating factor 2	Homo sapiens	121-124
34873089-0	2022	Impact of CYP2B6 genotype, TB therapy and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.	efavirenz	57-66	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	10-16
14711599-1	2003	BACKGROUND: In a retrospective study of HIV patients under antiretroviral therapy, we investigated the influence of the MDR1 genotype (C3435T) on plasma levels of lopinavir (LPV) and efavirenz (EFV).	efavirenz	194-197	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
12153332-6	2002	Upon review of available data, the antiretroviral agents zidovudine, stavudine, lamivudine, nevirapine, efavirenz and indinavir demonstrate consistent penetration into the CSF.	efavirenz	104-113	colony stimulating factor 2	Homo sapiens	172-175
11590528-9	2001	There was a statistically significant reduction in relative CD8+CD38+ from 62.2+/-16.3% at time of switching to EFV to 55.1+/-15.0% at week 36.	efavirenz	112-115	CD8a molecule	Homo sapiens	60-63
11225565-2	2001	Delavirdine, nevirapine, and efavirenz produced negligible inhibition of phenacetin O-deethylation (CYP1A2) or dextromethorphan O-demethylation (CYP2D6).	efavirenz	29-38	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	100-106
11225565-2	2001	Delavirdine, nevirapine, and efavirenz produced negligible inhibition of phenacetin O-deethylation (CYP1A2) or dextromethorphan O-demethylation (CYP2D6).	efavirenz	29-38	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	145-151
10622035-3	1999	Efavirenz is a mild inducer of CYP 3A4.	efavirenz	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-38
10082072-7	1999	Delaviridine is an inhibitor of CYP3A4, but nevirapine and efavirenz are inducers of CYP3A4.	efavirenz	59-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
9878993-7	1998	Once-daily efavirenz in combination with zidovudine plus lamivudine or indinavir or nelfinavir increased CD4+ cell counts and reduced HIV RNA plasma levels to below quantifiable levels (< 400 copies/ml) in HIV-infected patients.	efavirenz	11-20	CD4 molecule	Homo sapiens	105-108
34945777-9	2021	On multivariate analysis, CYP2B6*6 and ABCB1c.3435 C > T genotypes and low pre-treatment low-density lipoprotein (LDL) were significantly associated with higher plasma efavirenz concentration regardless of treatment duration.	efavirenz	168-177	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	26-32
34945777-9	2021	On multivariate analysis, CYP2B6*6 and ABCB1c.3435 C > T genotypes and low pre-treatment low-density lipoprotein (LDL) were significantly associated with higher plasma efavirenz concentration regardless of treatment duration.	efavirenz	168-177	ATP binding cassette subfamily B member 1	Homo sapiens	39-44
34945777-11	2021	(4) Conclusion: Pre-treatment LDL cholesterol and CYP2B6*6 and ABCB1c.3435 C > T genotypes predict efavirenz plasma exposure among HIV-infected children, but treatment-duration-dependent changes in plasma efavirenz exposure due to auto-induction are not statistically significant.	efavirenz	99-108	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	50-56
34945777-11	2021	(4) Conclusion: Pre-treatment LDL cholesterol and CYP2B6*6 and ABCB1c.3435 C > T genotypes predict efavirenz plasma exposure among HIV-infected children, but treatment-duration-dependent changes in plasma efavirenz exposure due to auto-induction are not statistically significant.	efavirenz	99-108	ATP binding cassette subfamily B member 1	Homo sapiens	63-68
12705974-2	2003	Therefore, a highly specific method is presented, which is capable of quantifying the different proteinase inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir) and non-nucleoside reverse transcriptase inhibitors (efavirenz, nelfinavir).	efavirenz	241-250	endogenous retrovirus group K member 25	Homo sapiens	96-106
12151999-1	2002	OBJECTIVE: The capacity of the non-nucleoside reverse transcriptase inhibitor efavirenz to induce either liver CYP3A4 or intestinal CYP3A4, or both, as well as intestinal P-glycoprotein, was evaluated in healthy volunteers during and after a 10-day treatment course with two different daily doses.	efavirenz	78-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117
12151999-1	2002	OBJECTIVE: The capacity of the non-nucleoside reverse transcriptase inhibitor efavirenz to induce either liver CYP3A4 or intestinal CYP3A4, or both, as well as intestinal P-glycoprotein, was evaluated in healthy volunteers during and after a 10-day treatment course with two different daily doses.	efavirenz	78-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138
12405865-13	2002	Rifampicin (rifampin), phenobarbital, phenytoin, carbamazepine, nevirapine, and efavirenz decrease methadone blood concentrations, probably by induction of CYP3A4 activity, which can result in severe withdrawal symptoms.	efavirenz	80-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-162
11159797-0	2001	Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.	efavirenz	11-20	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	45-51
11073762-6	2000	Six months after switching to efavirenz, there was a reduction in triglyceride levels (a decrease of 31%; P=.03) and fasting insulin resistance index (a decrease of 28%; P=.03), but total and high-density lipoprotein cholesterol and glucose did not change.	efavirenz	30-39	insulin	Homo sapiens	125-132
34768081-10	2021	These results imply that long-term EFV treatment causes synaptic dysfunction resulting in cognitive deficits, which might be induced by the enhanced pro-inflammatory cytokines IL-1beta and TNF-alpha via activating NF-kappaB pathway.	efavirenz	35-38	interleukin 1 alpha	Mus musculus	176-184
34768081-10	2021	These results imply that long-term EFV treatment causes synaptic dysfunction resulting in cognitive deficits, which might be induced by the enhanced pro-inflammatory cytokines IL-1beta and TNF-alpha via activating NF-kappaB pathway.	efavirenz	35-38	tumor necrosis factor	Mus musculus	189-198
34768081-10	2021	These results imply that long-term EFV treatment causes synaptic dysfunction resulting in cognitive deficits, which might be induced by the enhanced pro-inflammatory cytokines IL-1beta and TNF-alpha via activating NF-kappaB pathway.	efavirenz	35-38	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	214-223
34474119-0	2021	Effect of Albumin and CYP2B6 Polymorphisms on Exposure of Efavirenz: A Population Pharmacokinetic Analysis in Chinese HIV-infected Adults.	efavirenz	58-67	albumin	Homo sapiens	10-17
34474119-0	2021	Effect of Albumin and CYP2B6 Polymorphisms on Exposure of Efavirenz: A Population Pharmacokinetic Analysis in Chinese HIV-infected Adults.	efavirenz	58-67	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	22-28
34474119-9	2021	Efavirenz clearance was significantly influenced by CYP2B6 variants, including rs2099361, rs3745274, and rs2279343, along with albumin and weight.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	52-58
34474119-11	2021	Based on the CYP2B6 polymorphisms of patients, the recommended daily doses of efavirenz were 100 mg for CYP2B6 slow metabolizers, 400 or 600 mg for intermediate metabolizers, and 800 or 1000 mg for extensive metabolizers.	efavirenz	78-87	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	13-19
34474119-11	2021	Based on the CYP2B6 polymorphisms of patients, the recommended daily doses of efavirenz were 100 mg for CYP2B6 slow metabolizers, 400 or 600 mg for intermediate metabolizers, and 800 or 1000 mg for extensive metabolizers.	efavirenz	78-87	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	104-110
34474119-12	2021	CONCLUSIONS: Polymorphisms of CYP2B6, along with albumin and weight, resulted as the predictors of efavirenz pharmacokinetic variability, which could be used in prescribing optimal efavirenz doses.	efavirenz	99-108	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-36
34474119-12	2021	CONCLUSIONS: Polymorphisms of CYP2B6, along with albumin and weight, resulted as the predictors of efavirenz pharmacokinetic variability, which could be used in prescribing optimal efavirenz doses.	efavirenz	99-108	albumin	Homo sapiens	49-56
34474119-12	2021	CONCLUSIONS: Polymorphisms of CYP2B6, along with albumin and weight, resulted as the predictors of efavirenz pharmacokinetic variability, which could be used in prescribing optimal efavirenz doses.	efavirenz	181-190	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-36
34474119-12	2021	CONCLUSIONS: Polymorphisms of CYP2B6, along with albumin and weight, resulted as the predictors of efavirenz pharmacokinetic variability, which could be used in prescribing optimal efavirenz doses.	efavirenz	181-190	albumin	Homo sapiens	49-56
34235635-3	2021	Brain sterol flux is decreased in Cyp46a1-/- mice compared to wild-type mice and increased in 5XFAD mice (a model of Alzheimer"s disease) when they are treated with a small dose of efavirenz, a CYP46A1 activator.	efavirenz	181-190	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	34-41
34882770-2	2021	Efavirenz is primarily metabolized by cytochrome P450 2B6 (CYP2B6), with CYP2A6 as an accessory pathway.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	38-57
34882770-2	2021	Efavirenz is primarily metabolized by cytochrome P450 2B6 (CYP2B6), with CYP2A6 as an accessory pathway.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	59-65
34882770-2	2021	Efavirenz is primarily metabolized by cytochrome P450 2B6 (CYP2B6), with CYP2A6 as an accessory pathway.	efavirenz	0-9	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	73-79
34882770-6	2021	Genetic polymorphisms known to be associated with increased efavirenz plasma concentrations in CYP2B6 (rs3745274, rs28399499, rs4803419) and CYP2A6 (rs28399433) were selected and used to determine proportions of slow metabolizers.	efavirenz	60-69	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	141-147
34127577-8	2021	CLHIV on efavirenz (EFV) had consistently lower TNF-alpha and IL-6 compared with those on ritonavir-boosted lopinavir (LPV/r) at all time points.	efavirenz	9-18	tumor necrosis factor	Homo sapiens	48-57
34127577-8	2021	CLHIV on efavirenz (EFV) had consistently lower TNF-alpha and IL-6 compared with those on ritonavir-boosted lopinavir (LPV/r) at all time points.	efavirenz	9-18	interleukin 6	Homo sapiens	62-66
34127577-8	2021	CLHIV on efavirenz (EFV) had consistently lower TNF-alpha and IL-6 compared with those on ritonavir-boosted lopinavir (LPV/r) at all time points.	efavirenz	20-23	tumor necrosis factor	Homo sapiens	48-57
34127577-8	2021	CLHIV on efavirenz (EFV) had consistently lower TNF-alpha and IL-6 compared with those on ritonavir-boosted lopinavir (LPV/r) at all time points.	efavirenz	20-23	interleukin 6	Homo sapiens	62-66
34415664-0	2021	Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele.	efavirenz	28-37	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	124-130
34495458-9	2021	Co-administration of moderate CYP3A4 inducers (efavirenz, carbamazepine, phenytoin) was predicted to result in an average decrease in entrectinib exposure between 45 and 79%, with corresponding average decreases for M5 of approximately 50%.	efavirenz	47-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
34524919-2	2021	Our objective was to study the effects of switching from a protease inhibitor (PI) or efavirenz (EFV) to RAL on liver fat, body composition, and metabolic parameters among people living with HIV (PLWH) with high risk for nonalcoholic fatty liver disease (NAFLD).	efavirenz	86-95	FAT atypical cadherin 1	Homo sapiens	118-121
34524919-2	2021	Our objective was to study the effects of switching from a protease inhibitor (PI) or efavirenz (EFV) to RAL on liver fat, body composition, and metabolic parameters among people living with HIV (PLWH) with high risk for nonalcoholic fatty liver disease (NAFLD).	efavirenz	97-100	FAT atypical cadherin 1	Homo sapiens	118-121
34335044-0	2021	Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients.	efavirenz	46-55	sulfotransferase family 1A member 1	Homo sapiens	13-20
34335044-5	2021	Results: Patients with three or more copies of SULT1A1 had significantly lower median plasma EFV concentrations than those carrying two copies at week 12 (p=0.046) and SULT1A1*2 (c.638G>A) carriers had significantly lower median plasma EFV concentrations compared to those not carrying the variant at week 24 (p=0.048).	efavirenz	93-96	sulfotransferase family 1A member 1	Homo sapiens	47-54
34335044-5	2021	Results: Patients with three or more copies of SULT1A1 had significantly lower median plasma EFV concentrations than those carrying two copies at week 12 (p=0.046) and SULT1A1*2 (c.638G>A) carriers had significantly lower median plasma EFV concentrations compared to those not carrying the variant at week 24 (p=0.048).	efavirenz	236-239	sulfotransferase family 1A member 1	Homo sapiens	47-54
34335044-5	2021	Results: Patients with three or more copies of SULT1A1 had significantly lower median plasma EFV concentrations than those carrying two copies at week 12 (p=0.046) and SULT1A1*2 (c.638G>A) carriers had significantly lower median plasma EFV concentrations compared to those not carrying the variant at week 24 (p=0.048).	efavirenz	236-239	sulfotransferase family 1A member 1	Homo sapiens	168-175
34115651-9	2021	CYP2B6 516G > T, (P < 0.001) and CYP2B6 983T > C (P = 0.001) were each associated with hair efavirenz concentrations.	efavirenz	92-101	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
34115651-9	2021	CYP2B6 516G > T, (P < 0.001) and CYP2B6 983T > C (P = 0.001) were each associated with hair efavirenz concentrations.	efavirenz	92-101	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	33-39
34115651-13	2021	CONCLUSION: This study demonstrated approximately 3-fold and 2-fold higher efavirenz plasma and hair concentrations, respectively, among CYP2B6 516TT compared to 516GG.	efavirenz	75-84	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	137-143
34235635-3	2021	Brain sterol flux is decreased in Cyp46a1-/- mice compared to wild-type mice and increased in 5XFAD mice (a model of Alzheimer"s disease) when they are treated with a small dose of efavirenz, a CYP46A1 activator.	efavirenz	181-190	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	194-201
34939063-0	2021	Prolonged efavirenz exposure reduces peripheral oxytocin and vasopressin comparable to known drugs of addiction in male Sprague Dawley rats.	efavirenz	10-19	arginine vasopressin	Rattus norvegicus	61-72
34939063-4	2021	This study investigated whether sub-chronic EFV exposure, at a previously-determined rewarding dose, alters peripheral OT and VP levels versus that of a control,  9-tetrahydrocannabinol ( 9-THC), methamphetamine (MA) and cocaine.	efavirenz	44-47	arginine vasopressin	Rattus norvegicus	126-128
34100170-3	2021	To address this, we developed CD44 receptor-targeted, novel hyaluronic acid (HA)-coated nanostructured lipid carriers (NLCs) of efavirenz via washless layer-by-layer (LbL) assembly of HA and polyallylamine hydrochloride (PAH).	efavirenz	128-137	CD44 molecule (Indian blood group)	Homo sapiens	30-34
34093191-0	2021	Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy.	efavirenz	62-71	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	83-89
34093191-3	2021	UGT1A1*28 and CYP2B6 c.516G>T have been proposed to be related with higher toxicity by ATV and EFV, respectively.	efavirenz	95-98	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
34093191-3	2021	UGT1A1*28 and CYP2B6 c.516G>T have been proposed to be related with higher toxicity by ATV and EFV, respectively.	efavirenz	95-98	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	14-20
34280356-8	2021	Efavirenz use can negatively influence vitamin D levels and supplementation is necessary as a likely adjunct to improving CD4+ T cells, resulting in greater effectiveness of the treatment.	efavirenz	0-9	CD4 molecule	Homo sapiens	122-125
35489779-12	2022	The results suggest that the hydroxylated efavirenz metabolites may differ from efavirenz in how they interact with the CYP46A1 allosteric and active sites.	efavirenz	42-51	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	120-127
35461087-0	2022	Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1.	efavirenz	55-64	solute carrier family 2 member 1	Homo sapiens	175-181
35461087-10	2022	Putative in silico analysis indicated the antiretrovirals, apart from efavirenz, associated with the binding site of highest binding affinity to SLC2A1, similar to that of glucose.	efavirenz	70-79	solute carrier family 2 member 1	Homo sapiens	145-151
35428895-8	2022	Additionally, in the presence of strong or moderate CYP3A4 inducers, rifampicin and efavirenz, ipatasertib exposures were predicted to decrease by 86% and 74%, respectively.	efavirenz	84-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-58
35149540-10	2022	Significance Statement The in vivo Kp,uu,fetal of nelfinavir (P-gp substrate), efavirenz (BCRP substrate), and imatinib (P-gp and BCRP substrate) was successfully estimated using m-f- PBPK modeling.	efavirenz	79-88	BCR pseudogene 1	Homo sapiens	90-94
35512066-5	2022	One of the polymorphism in the CYP2B6 gene, 516G>T, particularly the 516T allele, is known to confer poor metabolism of EFV and NVP.	efavirenz	120-123	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	31-37
35489779-0	2022	The hydroxylation position rather than chirality determines how efavirenz metabolites activate CYP46A1 in vitro.	efavirenz	64-73	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	95-102
35489779-2	2022	In addition, (S)-EFV can interact off target with CYP46A1, the major cholesterol hydroxylating enzyme in the mammalian brain, and allosterically activate CYP46A1 at a small dose in mice and humans.	efavirenz	13-20	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	50-57
35489779-12	2022	The results suggest that the hydroxylated efavirenz metabolites may differ from efavirenz in how they interact with the CYP46A1 allosteric and active sites.	efavirenz	80-89	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	120-127
35489779-2	2022	In addition, (S)-EFV can interact off target with CYP46A1, the major cholesterol hydroxylating enzyme in the mammalian brain, and allosterically activate CYP46A1 at a small dose in mice and humans.	efavirenz	13-20	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	154-161
35489779-9	2022	This difference in binding to the allosteric sites determined, in turn, how CYP46A1 activity was changed in the co-incubations with (S)-EFV and either its metabolite or L-Glu.	efavirenz	132-139	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	76-83
35489779-10	2022	The results suggest EFV metabolites that could be more potent for CYP46A1 activation in vivo than (S)-EFV.	efavirenz	98-105	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	66-73
35099526-0	2022	Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.	efavirenz	85-94	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
35489779-11	2022	Significance Statement We found that not only efavirenz but also all its hydroxylated metabolites allosterically activate CYP46A1 in vitro The enzyme activation depended on the hydroxylation position but not the metabolite spatial configuration, and involved either one or two allosteric sites - for efavirenz, L-Glu or both.	efavirenz	46-55	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	122-129
35489779-11	2022	Significance Statement We found that not only efavirenz but also all its hydroxylated metabolites allosterically activate CYP46A1 in vitro The enzyme activation depended on the hydroxylation position but not the metabolite spatial configuration, and involved either one or two allosteric sites - for efavirenz, L-Glu or both.	efavirenz	300-309	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	122-129
35090905-5	2022	Additionally, efavirenz and rilpivirine increased ROS generation, disrupted Deltapsim and upregulated the mRNA and protein expression of CHOP and GRP78, key markers of endoplasmic reticulum stress.	efavirenz	14-23	DNA-damage inducible transcript 3	Rattus norvegicus	137-141
35090905-5	2022	Additionally, efavirenz and rilpivirine increased ROS generation, disrupted Deltapsim and upregulated the mRNA and protein expression of CHOP and GRP78, key markers of endoplasmic reticulum stress.	efavirenz	14-23	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	146-151
35107462-6	2022	Finally, the metabolite identification opportunities were also explored using efavirenz as an example drug with complex primary and secondary metabolism involving a combination of CYP, UGT and sulfotransferase enzymes.	efavirenz	78-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	180-183
35107462-6	2022	Finally, the metabolite identification opportunities were also explored using efavirenz as an example drug with complex primary and secondary metabolism involving a combination of CYP, UGT and sulfotransferase enzymes.	efavirenz	78-87	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	185-188
35235559-0	2022	Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.	efavirenz	89-98	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	11-30
35235559-0	2022	Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.	efavirenz	89-98	nuclear receptor subfamily 1 group I member 3	Homo sapiens	35-67
35235559-1	2022	The effects of genetic variation of cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) on efavirenz (EFV) plasma concentration was evaluated among 312 HIV patients in Nairobi Kenya.	efavirenz	122-125	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	36-55
35235559-1	2022	The effects of genetic variation of cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) on efavirenz (EFV) plasma concentration was evaluated among 312 HIV patients in Nairobi Kenya.	efavirenz	122-125	nuclear receptor subfamily 1 group I member 3	Homo sapiens	69-101
35194103-1	2022	Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone).	efavirenz	188-197	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	6-12
35194103-1	2022	Human CYP2B6 enzyme although constitutes relatively low proportion (1-4%) of hepatic cytochrome P450 content, it is the major catalyst of metabolism of several clinically important drugs (efavirenz, cyclophosphamide, bupropion, methadone).	efavirenz	188-197	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	85-100
35052789-0	2022	Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz.	efavirenz	81-90	NLR family pyrin domain containing 3	Homo sapiens	46-51
35115810-0	2022	The Cyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics.	efavirenz	59-68	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	4-10
35115810-12	2022	Genetic polymorphism of the CYP2B6 gene is prevalent among HIV/AIDs patients in the Niger Delta ethnic population on efavirenz-based HAART treatment, as the population having homozygous mutant gene or PM are >1% (6%).	efavirenz	117-126	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
35052789-2	2022	Efavirenz, an anti-HIV drug, induces deleterious actions in hepatocytes that could underlie induction of the NLRP3 inflammasome, an important regulator of inflammatory responses during liver injury.	efavirenz	0-9	NLR family pyrin domain containing 3	Homo sapiens	109-114
35052789-5	2022	Efavirenz triggered inflammation in hepatocytes, in a process that involved NF-kappaB and the NLRP3 inflammasome, and activated hepatic stellate cells (HSCs), thereby enhancing expression of inflammatory and fibrogenic markers.	efavirenz	0-9	nuclear factor kappa B subunit 1	Homo sapiens	76-85
35052789-5	2022	Efavirenz triggered inflammation in hepatocytes, in a process that involved NF-kappaB and the NLRP3 inflammasome, and activated hepatic stellate cells (HSCs), thereby enhancing expression of inflammatory and fibrogenic markers.	efavirenz	0-9	NLR family pyrin domain containing 3	Homo sapiens	94-99
35052789-8	2022	Efavirenz elicits a cell-specific activation of the NLRP3 inflammasome in hepatocytes and HSCs, but macrophages appear to counteract efavirenz-induced liver injury.	efavirenz	0-9	NLR family pyrin domain containing 3	Homo sapiens	52-57
33421254-0	2021	A novel association of efavirenz induced severe cutaneous adverse reactions with HLA- DRB1*03:01: A case-control study from North-East India.	efavirenz	23-32	major histocompatibility complex, class II, DR beta 1	Homo sapiens	81-90
33833550-0	2021	Erratum: Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum].	efavirenz	54-63	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	24-30
33758532-0	2021	Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana.	efavirenz	45-54	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	15-21
33758532-1	2021	Purpose: CYP2B6 liver enzyme metabolizes the two non-nucleoside reverse transcriptase inhibitors Efavirenz (EFV) and Nevirapine (NVP) used in the antiretroviral therapy (ART) regimens for HIV-infected individuals.	efavirenz	97-106	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	9-15
33758532-1	2021	Purpose: CYP2B6 liver enzyme metabolizes the two non-nucleoside reverse transcriptase inhibitors Efavirenz (EFV) and Nevirapine (NVP) used in the antiretroviral therapy (ART) regimens for HIV-infected individuals.	efavirenz	108-111	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	9-15
33336382-6	2021	In the clinical study, we confirmed a moderate induction of CYP2B6 (decrease in the efavirenz AUC by 79%) and 3A4 (decrease in the midazolam AUC by 68%) by metamizole.	efavirenz	84-93	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	60-66
33872945-1	2021	Human hepatic cytochrome P450 2B6 (CYP2B6) expressed is responsible for the metabolism of many drugs, such as cyclophosphamide, ifosfamid, and efavirenz.	efavirenz	143-152	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	14-33
33872945-1	2021	Human hepatic cytochrome P450 2B6 (CYP2B6) expressed is responsible for the metabolism of many drugs, such as cyclophosphamide, ifosfamid, and efavirenz.	efavirenz	143-152	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	35-41
32667979-2	2021	In a Phase 1 dolutegravir-efavirenz interaction study, mean dolutegravir Cmin decreased by 60% and 85% among CYP2B6 normal and slow/intermediate metabolizers, respectively.	efavirenz	26-35	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	109-115
32909316-6	2021	Isoniazid decreased efavirenz clearance by 7% in CYP2B6 normal metabolizers and 13% in slow and intermediate metabolizers.	efavirenz	20-29	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	49-55
32813881-2	2021	In 2016, the label of LNG was updated based on a drug-drug interaction (DDI) study showing a significant decrease in LNG exposure when co-administered with efavirenz, a known CYP3A4 inducer.	efavirenz	156-165	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-181
33421254-3	2021	To evaluate HLA class I and II allele frequencies in HIV patients on HAART who develop SCARs due to nevirapine (NVP] or efavirenz (EFZ] containing regime and compare this genotype composition with HAART tolerant patients and healthy organ donors.	efavirenz	120-129	major histocompatibility complex, class II, DR beta 1	Homo sapiens	12-15
33599403-2	2021	Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone.	efavirenz	85-94	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
33390085-7	2021	Drug resistance mutation M184V (ATG to GTA) (63.15%) associated with lamivudine and abacavir and K103N (AAG or AAA to AAU) (36.84%) associated with efavirenz and nevirapine were predominantly identified in first line ART failure patients.	efavirenz	148-157	N-methylpurine DNA glycosylase	Homo sapiens	104-107
33305262-0	2020	CYP46A1-dependent and independent effects of efavirenz treatment.	efavirenz	45-54	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	0-7
33526292-0	2021	Erratum to: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis [J Hepatol (2019); 70 (5): 930-940].	efavirenz	59-68	nuclear receptor subfamily 1 group I member 2	Homo sapiens	79-82
31942947-9	2021	The differences in GMR (90%CI) of TFV AUC, C24, and EFV C24 at week 5 versus week 8 were 0.86 (0.80-0.93), p=0.002; 0.83 (0.75-0.93), p=0.006; and EFV C24 was 0.91 (0.85-0.97), p=0.02, respectively.	efavirenz	52-55	colony stimulating factor 2 receptor subunit alpha	Homo sapiens	19-22
31942947-9	2021	The differences in GMR (90%CI) of TFV AUC, C24, and EFV C24 at week 5 versus week 8 were 0.86 (0.80-0.93), p=0.002; 0.83 (0.75-0.93), p=0.006; and EFV C24 was 0.91 (0.85-0.97), p=0.02, respectively.	efavirenz	147-150	colony stimulating factor 2 receptor subunit alpha	Homo sapiens	19-22
32815870-6	2021	In multivariable analyses, NAT2 slow acetylators had greater week 4 plasma concentrations of rifapentine (P = 2.6 x 10) and 25-desacetyl rifapentine (P = 7.0 x 10) among all participants, and in efavirenz and nevirapine subgroups.	efavirenz	195-204	N-acetyltransferase 2	Homo sapiens	27-31
32815870-7	2021	NAT2 slow acetylators also had greater plasma efavirenz and nevirapine concentration increases from baseline to week 4, and greater decreases from baseline in clearance.	efavirenz	46-55	N-acetyltransferase 2	Homo sapiens	0-4
32815870-8	2021	CYP2B6 poor metabolizers had greater efavirenz concentrations at all weeks and greater nevirapine concentrations at baseline.	efavirenz	37-46	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
32815870-10	2021	CONCLUSIONS: Among HIV-positive individuals receiving efavirenz or nevirapine, and who then initiated rifapentine plus isoniazid in A5279, NAT2 slow acetylators had greater rifapentine and 25-desacetyl rifapentine concentrations, and greater increases from baseline in plasma efavirenz and nevirapine concentrations.	efavirenz	54-63	N-acetyltransferase 2	Homo sapiens	139-143
32815870-10	2021	CONCLUSIONS: Among HIV-positive individuals receiving efavirenz or nevirapine, and who then initiated rifapentine plus isoniazid in A5279, NAT2 slow acetylators had greater rifapentine and 25-desacetyl rifapentine concentrations, and greater increases from baseline in plasma efavirenz and nevirapine concentrations.	efavirenz	276-285	N-acetyltransferase 2	Homo sapiens	139-143
33452585-10	2021	Amlodipine apparent clearance was influenced by both CYP3A4 inhibitors and efavirenz (CYP3A4 inducer).	efavirenz	75-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92
33217171-7	2021	The combined LNG-EE PBPK model was verified regarding CYP3A4-mediated interaction by comparing to published clinical DDI study data with carbamazepine, rifampicin, and efavirenz (CYP3A4 inducers).	efavirenz	168-177	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	179-185
33355828-1	2020	Background: Africans exhibit great diversity in cytochrome P450 2B6 isoenzyme (CYP2B6), the major enzyme in efavirenz metabolism.	efavirenz	108-117	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	48-77
33355828-1	2020	Background: Africans exhibit great diversity in cytochrome P450 2B6 isoenzyme (CYP2B6), the major enzyme in efavirenz metabolism.	efavirenz	108-117	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	79-85
33355828-2	2020	Aim: We examined the frequency of two functional single nucleotide polymorphisms (SNPs) of the CYP2B6 pharmacogene in HIV-infected Nigerians on efavirenz-based antiretroviral therapy.	efavirenz	144-153	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	95-101
33305262-5	2020	Previously we found that treatment of 5XFAD mice, an Alzheimer"s disease model, with a small dose of anti-HIV drug efavirenz allosterically activated cytochrome P450 46A1 in the brain and mitigated several disease manifestations.	efavirenz	115-124	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	150-170
33305262-7	2020	Efavirenz-treated versus control Cyp46a1-/- 5XFAD and 5XFAD mice were compared for the brain sterol and steroid hormone content, amyloid beta burden, protein and mRNA expression as well as synaptic ultrastructure.	efavirenz	0-9	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	33-40
33305262-8	2020	We found that the cytochrome P450 46A1-dependent efavirenz effects included changes in the levels of brain sterols, steroid hormones, and such proteins as glial fibrillary acidic protein, Iba1, Munc13-1, post-synaptic density-95, gephyrin, synaptophysin and synapsin-1.	efavirenz	49-58	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	18-38
33305262-8	2020	We found that the cytochrome P450 46A1-dependent efavirenz effects included changes in the levels of brain sterols, steroid hormones, and such proteins as glial fibrillary acidic protein, Iba1, Munc13-1, post-synaptic density-95, gephyrin, synaptophysin and synapsin-1.	efavirenz	49-58	glial fibrillary acidic protein	Mus musculus	155-186
33305262-8	2020	We found that the cytochrome P450 46A1-dependent efavirenz effects included changes in the levels of brain sterols, steroid hormones, and such proteins as glial fibrillary acidic protein, Iba1, Munc13-1, post-synaptic density-95, gephyrin, synaptophysin and synapsin-1.	efavirenz	49-58	induction of brown adipocytes 1	Mus musculus	188-192
33305262-8	2020	We found that the cytochrome P450 46A1-dependent efavirenz effects included changes in the levels of brain sterols, steroid hormones, and such proteins as glial fibrillary acidic protein, Iba1, Munc13-1, post-synaptic density-95, gephyrin, synaptophysin and synapsin-1.	efavirenz	49-58	unc-13 homolog A	Mus musculus	194-202
33305262-8	2020	We found that the cytochrome P450 46A1-dependent efavirenz effects included changes in the levels of brain sterols, steroid hormones, and such proteins as glial fibrillary acidic protein, Iba1, Munc13-1, post-synaptic density-95, gephyrin, synaptophysin and synapsin-1.	efavirenz	49-58	gephyrin	Mus musculus	230-238
33305262-8	2020	We found that the cytochrome P450 46A1-dependent efavirenz effects included changes in the levels of brain sterols, steroid hormones, and such proteins as glial fibrillary acidic protein, Iba1, Munc13-1, post-synaptic density-95, gephyrin, synaptophysin and synapsin-1.	efavirenz	49-58	synaptophysin	Mus musculus	240-253
33305262-8	2020	We found that the cytochrome P450 46A1-dependent efavirenz effects included changes in the levels of brain sterols, steroid hormones, and such proteins as glial fibrillary acidic protein, Iba1, Munc13-1, post-synaptic density-95, gephyrin, synaptophysin and synapsin-1.	efavirenz	49-58	synapsin I	Mus musculus	258-268
33305262-15	2020	This study further confirmed that cytochrome P450 46A1 is a key enzyme for cholesterol homeostasis in the brain and that the therapeutic efavirenz effects on 5XFAD mice are likely realized via cytochrome P450 46A1 activation.	efavirenz	137-146	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	34-54
33305262-15	2020	This study further confirmed that cytochrome P450 46A1 is a key enzyme for cholesterol homeostasis in the brain and that the therapeutic efavirenz effects on 5XFAD mice are likely realized via cytochrome P450 46A1 activation.	efavirenz	137-146	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	193-213
32960272-0	2021	CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.	efavirenz	69-78	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
33155233-10	2020	Efavirenz acts as a serotonin 5-HT2A receptor antagonist, a serotonin-dopamine reuptake inhibitor, an inhibitor of monoamine oxidase (MAO) and a vesicular monoamine transporter 2 (VMAT2) inhibitor, which are mechanisms common with many psychotropic drugs.	efavirenz	0-9	5-hydroxytryptamine receptor 2A	Homo sapiens	20-45
33155233-10	2020	Efavirenz acts as a serotonin 5-HT2A receptor antagonist, a serotonin-dopamine reuptake inhibitor, an inhibitor of monoamine oxidase (MAO) and a vesicular monoamine transporter 2 (VMAT2) inhibitor, which are mechanisms common with many psychotropic drugs.	efavirenz	0-9	solute carrier family 18 member A2	Homo sapiens	180-185
33116922-12	2020	Health-care providers should give attention to patients on efavirenz therapy to monitor for CNS adverse events, especially for patients who have low CD4 count, advanced disease, comorbidities, low income and are older in age.	efavirenz	59-68	CD4 molecule	Homo sapiens	149-152
32960272-2	2021	Loss-of-function polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we hypothesized would impair weight gain among people living with human immunodeficiency virus (HIV; PLWH) starting efavirenz-based antiretroviral therapy (ART).	efavirenz	58-67	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-40
32960272-2	2021	Loss-of-function polymorphisms in CYP2B6 result in higher efavirenz concentrations, which we hypothesized would impair weight gain among people living with human immunodeficiency virus (HIV; PLWH) starting efavirenz-based antiretroviral therapy (ART).	efavirenz	206-215	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-40
32960272-11	2021	CONCLUSIONS: CYP2B6 metaboliser genotype was associated with weight gain in PLWH starting efavirenz-based ART.	efavirenz	90-99	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	13-19
32590137-8	2020	Osteocalcin (ng/mL) was higher in the LPV/r than efavirenz group both at 8 weeks (88.6 vs. 67.3, p = 0.001) and 2 years (67.6 vs. 49.8, p = 0.001).	efavirenz	49-58	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
32451120-2	2020	Polymorphism of CYP2B6 516G > T has been found to predominantly contribute to efavirenz variability.	efavirenz	78-87	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
32905132-5	2020	Notable examples include oseltamivir which may act as MAO inhibitor and efavirenz, which has an affinity for serotonin 5-HT2 and GABA-A receptors, the serotonin transporter, the MAO enzyme, and the vesicular monoamine transporter, with subjective effects which may be similar to those of the psychedelic hallucinogen lysergic acid diethylamide (LSD).	efavirenz	72-81	solute carrier family 6 member 4	Homo sapiens	151-172
32702281-5	2020	Compared to regimens containing lopinavir, we found that atazanavir-, efavirenz-, and raltegravir-based regimens were superior in achieving both outcomes after adjustment for age, social vulnerability index, time under ART, baseline CD4+ cell count, and baseline HIV VL.	efavirenz	70-79	CD4 molecule	Homo sapiens	233-236
32310900-8	2020	In adjusted models, children exposed to efavirenz at any time during pregnancy had higher risk of neurologic case status (aRR = 1.53, 95% CI 0.94--2.51).	efavirenz	40-49	arrestin beta 1	Homo sapiens	122-129
32310900-9	2020	This association was stronger when comparing efavirenz exposure at conception to no exposure during pregnancy (aRR = 1.92, 95% CI 1.09--3.36) and considering follow-up and case diagnosis only through age 2 (aRR = 2.14, 95% CI 1.11--4.12).	efavirenz	45-54	arrestin beta 1	Homo sapiens	111-118
32310900-9	2020	This association was stronger when comparing efavirenz exposure at conception to no exposure during pregnancy (aRR = 1.92, 95% CI 1.09--3.36) and considering follow-up and case diagnosis only through age 2 (aRR = 2.14, 95% CI 1.11--4.12).	efavirenz	45-54	arrestin beta 2	Homo sapiens	207-214
32829410-5	2021	Associations were characterized with CYP2B6 and UGT1A1 genotypes that affect efavirenz and INSTI metabolism, respectively.	efavirenz	77-86	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	37-43
32829410-5	2021	Associations were characterized with CYP2B6 and UGT1A1 genotypes that affect efavirenz and INSTI metabolism, respectively.	efavirenz	77-86	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	48-54
32829410-10	2021	In the clinical trials cohort (N=462), CYP2B6 slow metabolizers had lesser weight gain at week 48 among participants receiving efavirenz with tenofovir disoproxil fumarate (p=0.001) but not those receiving efavirenz with abacavir (p=0.65).	efavirenz	127-136	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	39-45
32829410-10	2021	In the clinical trials cohort (N=462), CYP2B6 slow metabolizers had lesser weight gain at week 48 among participants receiving efavirenz with tenofovir disoproxil fumarate (p=0.001) but not those receiving efavirenz with abacavir (p=0.65).	efavirenz	206-215	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	39-45
32829410-12	2021	CONCLUSIONS: Among patients who switched from efavirenz- to INSTI-based therapy, CYP2B6 genotype was associated with weight gain, possibly reflecting withdrawal of the inhibitory effect of higher efavirenz concentrations on weight gain.	efavirenz	46-55	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	81-87
32829410-12	2021	CONCLUSIONS: Among patients who switched from efavirenz- to INSTI-based therapy, CYP2B6 genotype was associated with weight gain, possibly reflecting withdrawal of the inhibitory effect of higher efavirenz concentrations on weight gain.	efavirenz	196-205	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	81-87
32377759-0	2020	Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6?	efavirenz	53-62	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	128-134
32838647-5	2020	CYP2B6 516G>T, 785A>G, 18492C>T and ABCB1 3435C>T T/C were associated with higher efavirenz plasma levels in the standard but not the lower-dose group.	efavirenz	82-91	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
32838647-5	2020	CYP2B6 516G>T, 785A>G, 18492C>T and ABCB1 3435C>T T/C were associated with higher efavirenz plasma levels in the standard but not the lower-dose group.	efavirenz	82-91	ATP binding cassette subfamily B member 1	Homo sapiens	36-41
32451120-4	2020	This study aimed to develop a population model of the pharmacokinetic properties of efavirenz, and to investigate the impact of patients" characteristics and CYP2B6 516G > T polymorphism on the pharmacokinetic properties of efavirenz.	efavirenz	224-233	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	158-164
32451120-7	2020	A 1-compartment model with first-order absorption and elimination was used for describing the pharmacokinetic properties of efavirenz.	efavirenz	124-133	BCL2 related protein A1	Homo sapiens	0-3
32451120-9	2020	The efavirenz oral clearance were 11.9, 8.0, and 2.8 L/h in patients weighing 57 kg and having the CYP2B6 516 GG, 516 GT, and 516 TT genotypes, respectively.	efavirenz	4-13	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	99-105
32451120-12	2020	IMPLICATION: The results from this study provide a rationale for efavirenz dose adjustment based on CYP2B6 516G > T polymorphism in Thai HIV-infected patients, which could help to improve treatment outcomes in this population.	efavirenz	65-74	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	100-106
31617715-0	2020	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.	efavirenz	57-66	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	23-43
31617715-0	2020	In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.	efavirenz	57-66	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	45-52
31617715-2	2020	Currently CYP46A1 is being evaluated in a clinical trial for activation by small doses of the anti-HIV drug efavirenz.	efavirenz	108-117	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	10-17
31617715-3	2020	Eight efavirenz-related compounds were investigated for CYP46A1 activation in vitro, induction of a CYP46A1 spectral response and spectral Kd values, interaction with the P450 allosteric sites, and a model of binding to the enzyme active site.	efavirenz	6-15	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	100-107
31617715-4	2020	We gained insight into structure-activity relationships of efavirenz for CYP46A1 activation and found that the investigated efavirenz primary metabolites are stronger and better activators of CYP46A1 than efavirenz.	efavirenz	59-68	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	73-80
31617715-4	2020	We gained insight into structure-activity relationships of efavirenz for CYP46A1 activation and found that the investigated efavirenz primary metabolites are stronger and better activators of CYP46A1 than efavirenz.	efavirenz	59-68	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	192-199
31617715-4	2020	We gained insight into structure-activity relationships of efavirenz for CYP46A1 activation and found that the investigated efavirenz primary metabolites are stronger and better activators of CYP46A1 than efavirenz.	efavirenz	124-133	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	73-80
31617715-4	2020	We gained insight into structure-activity relationships of efavirenz for CYP46A1 activation and found that the investigated efavirenz primary metabolites are stronger and better activators of CYP46A1 than efavirenz.	efavirenz	124-133	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	192-199
31617715-4	2020	We gained insight into structure-activity relationships of efavirenz for CYP46A1 activation and found that the investigated efavirenz primary metabolites are stronger and better activators of CYP46A1 than efavirenz.	efavirenz	124-133	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	73-80
31617715-4	2020	We gained insight into structure-activity relationships of efavirenz for CYP46A1 activation and found that the investigated efavirenz primary metabolites are stronger and better activators of CYP46A1 than efavirenz.	efavirenz	124-133	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	192-199
31617715-6	2020	The results suggest structural modifications of efavirenz to further increase CYP46A1 activation without inhibition at high compound concentrations.	efavirenz	48-57	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	78-85
31617715-7	2020	It is possible that not only efavirenz but its metabolites activate CYP46A1 in vivo.	efavirenz	29-38	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	68-75
31845585-3	2020	The anti-HIV drug efavirenz activates CYP46A1 at low drug levels while inhibiting the enzyme activity at the high dose used in clinical practice.	efavirenz	18-27	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	38-45
31845585-4	2020	Synthetic analogs and hydroxylated metabolites of efavirenz enhance CYP46A1 activity, with reduced unwanted enzyme inhibition at higher concentrations.	efavirenz	50-59	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	68-75
31845585-5	2020	These observations provide a platform for structural modifications of efavirenz to modulate CYP46A1 activity as a therapeutic target of brain disorders such as Alzheimer"s disease, for which currently no treatment is available.	efavirenz	70-79	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	92-99
31324697-0	2019	Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	47-53
31628422-0	2020	Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers.	efavirenz	85-94	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	13-19
31628422-2	2020	Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well-known predictor of efavirenz disposition.	efavirenz	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
31628422-2	2020	Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well-known predictor of efavirenz disposition.	efavirenz	76-85	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	17-20
31628422-2	2020	Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well-known predictor of efavirenz disposition.	efavirenz	76-85	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	22-28
31628422-5	2020	In this study, we evaluated the influence of 11 single-nucleotide polymorphisms (SNPs) in CYP2B6, CYP2A6, CYP3A and ABCB1 (ATP-binding cassette sub-family B member 1) on the pharmacokinetics and safety of efavirenz after single oral dose administration to 47 healthy volunteers.	efavirenz	205-214	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	90-96
31628422-5	2020	In this study, we evaluated the influence of 11 single-nucleotide polymorphisms (SNPs) in CYP2B6, CYP2A6, CYP3A and ABCB1 (ATP-binding cassette sub-family B member 1) on the pharmacokinetics and safety of efavirenz after single oral dose administration to 47 healthy volunteers.	efavirenz	205-214	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-111
31628422-5	2020	In this study, we evaluated the influence of 11 single-nucleotide polymorphisms (SNPs) in CYP2B6, CYP2A6, CYP3A and ABCB1 (ATP-binding cassette sub-family B member 1) on the pharmacokinetics and safety of efavirenz after single oral dose administration to 47 healthy volunteers.	efavirenz	205-214	ATP binding cassette subfamily B member 1	Homo sapiens	116-121
31628422-5	2020	In this study, we evaluated the influence of 11 single-nucleotide polymorphisms (SNPs) in CYP2B6, CYP2A6, CYP3A and ABCB1 (ATP-binding cassette sub-family B member 1) on the pharmacokinetics and safety of efavirenz after single oral dose administration to 47 healthy volunteers.	efavirenz	205-214	ATP binding cassette subfamily B member 1	Homo sapiens	123-165
31628422-6	2020	We designed and validated a CYP2B6 activity score model based on two CYP2B6 SNPs (G516T and rs4803419) that predicted efavirenz disposition better than G516T alone.	efavirenz	118-127	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
31628422-6	2020	We designed and validated a CYP2B6 activity score model based on two CYP2B6 SNPs (G516T and rs4803419) that predicted efavirenz disposition better than G516T alone.	efavirenz	118-127	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	69-75
32106141-8	2020	At day 21 in the efavirenz group, CYP2B6 genotype was associated with increased plasma efavirenz exposure (P = 3.2 x 10), decreased plasma concentrations of etonogestrel (P = 1.7 x 10), and decreased ethinyl estradiol (P = 6.7 x 10).	efavirenz	17-26	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-40
32106141-8	2020	At day 21 in the efavirenz group, CYP2B6 genotype was associated with increased plasma efavirenz exposure (P = 3.2 x 10), decreased plasma concentrations of etonogestrel (P = 1.7 x 10), and decreased ethinyl estradiol (P = 6.7 x 10).	efavirenz	87-96	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-40
32106141-9	2020	Compared to controls, efavirenz reduced median etonogestrel concentrations by at least 93% in CYP2B6 slow metabolizers versus approximately 75% in normal and intermediate metabolizers.	efavirenz	22-31	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	94-100
32106141-10	2020	Efavirenz reduced median ethinyl estradiol concentrations by 75% in CYP2B6 slow metabolizers versus approximately 41% in normal and intermediate metabolizers.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	68-74
32106141-11	2020	CONCLUSION: CYP2B6 slow metabolizer genotype worsens the pharmacokinetic interaction of efavirenz with hormonal contraceptives administered by vaginal ring.	efavirenz	88-97	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	12-18
32106141-12	2020	Efavirenz dose reduction in CYP2B6 slow metabolizers may reduce, but will likely not eliminate, this interaction.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
31777202-7	2020	Efavirenz, an activator of CYP46A1 that is known to penetrate the blood-brain barrier, inhibited GBM growth in vivo.	efavirenz	0-9	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	27-34
31339646-1	2019	We investigated the effect of efavirenz on the activities of cytochrome P450 (CYP)1A2, CYP2A6, xanthine oxidase (XO), and N-acetyltransferase 2 (NAT2), using caffeine as a probe.	efavirenz	30-39	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	61-85
31339646-1	2019	We investigated the effect of efavirenz on the activities of cytochrome P450 (CYP)1A2, CYP2A6, xanthine oxidase (XO), and N-acetyltransferase 2 (NAT2), using caffeine as a probe.	efavirenz	30-39	N-acetyltransferase 2	Homo sapiens	122-143
31006110-2	2019	Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	68-92
31006110-2	2019	Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	120-126
31006110-3	2019	We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.	efavirenz	90-99	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	121-127
31324697-4	2019	CYP2B6 genetics and drug interactions are major determinants of clinical efavirenz disposition and dose adjustment.	efavirenz	73-82	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
31324697-6	2019	Metabolism of R-efavirenz by CYP2B6 remains unexplored.	efavirenz	14-25	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	29-35
31324697-8	2019	This investigation also evaluated R-efavirenz hydroxylation by wild-type CYP2B6.1 and CYP2B6 variants.	efavirenz	34-45	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	73-79
31324697-11	2019	Rates of R-efavirenz metabolism were approximately 1/10 those of S-efavirenz for wild-type CYP2B6.1 and variants.	efavirenz	9-20	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	91-97
31324697-12	2019	On the basis of Clmax values, there was 14-fold enantioselectivity (S > R-efavirenz) for wild-type CYP2B6.1, and 5- to 22-fold differences for other CYP2B6 variants.	efavirenz	72-83	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	99-105
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	186-195	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	29-35
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	186-195	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	186-195	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	186-195	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	186-195	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	291-300	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	29-35
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	291-300	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	291-300	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	291-300	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
31324697-13	2019	These results show that both CYP2B6 516G > T (CYP2B6*6 and CYP2B6*9) and 983T > C (CYP2B6*16 and CYP2B6*18) polymorphisms cause canonical diminishment or loss-of-function variants for S-efavirenz 8-hydroxylation, provide a mechanistic basis for known clinical pharmacogenetic differences in efavirenz disposition, and may predict additional clinically important variant alleles.	efavirenz	291-300	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
31324697-14	2019	Efavirenz is the most stereoselective CYP2B6 drug substrate yet identified and may be a useful probe for the CYP2B6 active site and catalytic mechanisms.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	38-44
31324697-14	2019	Efavirenz is the most stereoselective CYP2B6 drug substrate yet identified and may be a useful probe for the CYP2B6 active site and catalytic mechanisms.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	109-115
31324697-16	2019	Expressed CYP2B6 with 516G>T (CYP2B6*6 and CYP2B6*9), and 983T>C (CYP2B6*16 and CYP2B6*18) polymorphisms had a diminishment or loss of function for efavirenz 8-hydroxylation.	efavirenz	148-157	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	10-16
31324697-19	2019	With greater than 10-fold enantioselectivity (S- vs. R- metabolism), efavirenz is the most stereoselective CYP2B6 drug substrate yet identified.	efavirenz	69-78	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	107-113
31299074-7	2019	In the efavirenz group CYP2B6 516 G>T was associated with 43% lower etonogestrel Cmin and 34% lower AUC0-24weeks.	efavirenz	7-16	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	23-29
31299074-10	2019	Efavirenz plus the etonogestrel contraceptive implant results in a detrimental drug-drug interaction irrespective of patient genetics, which is worsened in women possessing variant alleles for these CYP2B6 SNPs.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	199-205
31409277-10	2019	Median body mass index and CD4 count at efavirenz commencement was 21 (IQR: 19-23) and 260 cells/mm3 (IQR: 126-412) respectively.	efavirenz	40-49	CD4 molecule	Homo sapiens	27-30
31243456-2	2019	Our objectives are to characterize the effects of rifampicin- and isoniazid-containing anti-TB therapy and CYP2B6 activity on efavirenz concentrations in children, using non-linear mixed-effects modelling.	efavirenz	126-135	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	107-113
31075350-9	2019	Also, in EFV-treated cells, p62 was associated with mitochondria, which may be related to the mito-protective function of this autophagic protein.	efavirenz	9-12	sequestosome 1	Homo sapiens	28-31
31063705-0	2019	The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment.	efavirenz	68-77	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	88-95
31063705-0	2019	The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment.	efavirenz	134-143	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	88-95
31063705-1	2019	Efavirenz (EFV) is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is the major brain cholesterol hydroxylase.	efavirenz	0-9	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	63-70
31063705-1	2019	Efavirenz (EFV) is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is the major brain cholesterol hydroxylase.	efavirenz	11-14	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	63-70
31063705-9	2019	The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment.	efavirenz	68-77	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	88-95
31241542-1	2019	BACKGROUND: CYP2B6 516 genotype-directed dosing improves efavirenz (EFV) exposures in HIV-infected children younger than 36 months, but such data are lacking in those with tuberculosis (TB) coinfection.	efavirenz	57-66	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	12-18
31241542-1	2019	BACKGROUND: CYP2B6 516 genotype-directed dosing improves efavirenz (EFV) exposures in HIV-infected children younger than 36 months, but such data are lacking in those with tuberculosis (TB) coinfection.	efavirenz	68-71	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	12-18
30859284-17	2019	EFV on nongated-NCCT may serve as an independent biomarker for predicting coronary artery disease with accuracy equivalent to that of EFV on gated CCTA.	efavirenz	0-3	solute carrier family 12 member 3	Homo sapiens	16-20
31062296-0	2019	CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice.	efavirenz	22-31	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	0-7
31062296-2	2019	Efavirenz is assessed for activation of cytochrome P450 46A1 (CYP46A1), a CNS-specific enzyme that converts cholesterol to 24-hydroxycholesterol.	efavirenz	0-9	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	40-60
31062296-2	2019	Efavirenz is assessed for activation of cytochrome P450 46A1 (CYP46A1), a CNS-specific enzyme that converts cholesterol to 24-hydroxycholesterol.	efavirenz	0-9	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	62-69
30918485-14	2019	As reduced dose EFV has a lower toxicity profile, we predicted the reduction in HIV infection when 400 mg EFV-PrEP was poorly adhered to, when it was taken "on demand" and as post-exposure prophylaxis (PEP).	efavirenz	16-19	prolyl endopeptidase	Homo sapiens	202-205
31223608-14	2019	EFV reduced RANKL-mediated osteoclast formation and activation by inhibiting expression of nuclear factor of activated T cells 1, a key factor of osteoclastogenesis.	efavirenz	0-3	TNF superfamily member 11	Homo sapiens	12-17
30677459-2	2019	Herein, we investigated the role of pregnane X receptor (PXR) in mediating the adverse effects of efavirenz on lipid homeostasis.	efavirenz	98-107	nuclear receptor subfamily 1, group I, member 2	Mus musculus	36-55
30677459-2	2019	Herein, we investigated the role of pregnane X receptor (PXR) in mediating the adverse effects of efavirenz on lipid homeostasis.	efavirenz	98-107	nuclear receptor subfamily 1, group I, member 2	Mus musculus	57-60
30677459-5	2019	RESULTS: We found that efavirenz is a potent PXR-selective agonist that can efficiently activate PXR and induce its target gene expression in vitro and in vivo.	efavirenz	23-32	nuclear receptor subfamily 1, group I, member 2	Mus musculus	45-48
30677459-5	2019	RESULTS: We found that efavirenz is a potent PXR-selective agonist that can efficiently activate PXR and induce its target gene expression in vitro and in vivo.	efavirenz	23-32	nuclear receptor subfamily 1, group I, member 2	Mus musculus	97-100
30220106-7	2019	The HIV-1-proteins Tat, Gp120 and Nef in particular, the proinflammatory cytokine, TNF-alpha, and the antiretroviral drugs Efavirenz and Lopinavir, most commonly postulated to be primary causal agents of endothelial dysfunction, are also discussed.	efavirenz	123-132	S100 calcium binding protein B	Homo sapiens	34-37
29635009-0	2018	The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy.	efavirenz	58-67	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	14-20
30535366-8	2019	CYP2A6 -48A C was independently associated with higher CSF 8-hydroxy-efavirenz:efavirenz ratio (beta = 0.54, P = 0.048).	efavirenz	69-78	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	0-6
30535366-9	2019	CYP2B6 rs2279345 polymorphism was associated with lower plasma 7-hydroxy-efavirenz:efavirenz ratio in multivariate analyses (P < 0.05).	efavirenz	73-82	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
30201214-1	2018	Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-individual variation in the metabolism of clinically important drugs, including cyclophosphamide, bupropion, methadone and efavirenz (EFZ).	efavirenz	198-207	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	26-45
30201214-1	2018	Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-individual variation in the metabolism of clinically important drugs, including cyclophosphamide, bupropion, methadone and efavirenz (EFZ).	efavirenz	198-207	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	47-53
30201214-1	2018	Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-individual variation in the metabolism of clinically important drugs, including cyclophosphamide, bupropion, methadone and efavirenz (EFZ).	efavirenz	209-212	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	26-45
30201214-1	2018	Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-individual variation in the metabolism of clinically important drugs, including cyclophosphamide, bupropion, methadone and efavirenz (EFZ).	efavirenz	209-212	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	47-53
29868865-12	2018	Conclusions: In a highly admixed Brazilian cohort, the CYP2B6 slow metabolizer genotype was associated with an increased risk of efavirenz adverse effects.	efavirenz	129-138	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	55-61
31039134-3	2019	Both rifampicin and efavirenz are activators of the pregnane X receptor (PXR), a transcription factor with significant inter-species differences in ligand-dependent activation.	efavirenz	20-29	nuclear receptor subfamily 1 group I member 2	Homo sapiens	52-71
31039134-3	2019	Both rifampicin and efavirenz are activators of the pregnane X receptor (PXR), a transcription factor with significant inter-species differences in ligand-dependent activation.	efavirenz	20-29	nuclear receptor subfamily 1 group I member 2	Homo sapiens	73-76
30442673-2	2019	Here we demonstrate that EFV stimulates the activation in primary hepatocytes of key cell stress regulators: inositol-requiring 1alpha (IRE1alpha) and X-box binding protein 1 (XBP1).	efavirenz	25-28	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	109-134
30442673-2	2019	Here we demonstrate that EFV stimulates the activation in primary hepatocytes of key cell stress regulators: inositol-requiring 1alpha (IRE1alpha) and X-box binding protein 1 (XBP1).	efavirenz	25-28	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	136-145
30442673-2	2019	Here we demonstrate that EFV stimulates the activation in primary hepatocytes of key cell stress regulators: inositol-requiring 1alpha (IRE1alpha) and X-box binding protein 1 (XBP1).	efavirenz	25-28	X-box binding protein 1	Mus musculus	151-174
30442673-2	2019	Here we demonstrate that EFV stimulates the activation in primary hepatocytes of key cell stress regulators: inositol-requiring 1alpha (IRE1alpha) and X-box binding protein 1 (XBP1).	efavirenz	25-28	X-box binding protein 1	Mus musculus	176-180
30442673-3	2019	Following EFV exposure, XBP1 splicing (indicating activation) was increased 35.7-fold in primary human hepatocytes.	efavirenz	10-13	X-box binding protein 1	Homo sapiens	24-28
30442673-5	2019	Of note, with EFV treatment, 47.2% of mouse hepatocytes were apoptotic; which was decreased to 23.9% in the presence of STF 083010, an inhibitor of XBP1 splicing.	efavirenz	14-17	X-box binding protein 1	Mus musculus	148-152
30442673-7	2019	Interestingly, incubation with the primary metabolite of EFV, 8-hydroxyefavirenz (8-OHEFV), only resulted in 10.3- and 2.9-fold increased XBP1 splicing in human and mouse hepatocytes and no change in levels of p-IRE1alpha in mouse hepatocytes.	efavirenz	57-60	X-box binding protein 1	Homo sapiens	138-142
30442673-7	2019	Interestingly, incubation with the primary metabolite of EFV, 8-hydroxyefavirenz (8-OHEFV), only resulted in 10.3- and 2.9-fold increased XBP1 splicing in human and mouse hepatocytes and no change in levels of p-IRE1alpha in mouse hepatocytes.	efavirenz	57-60	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	212-221
30442673-8	2019	To further probe the structure-activity relationship of IRE1alpha-XBP1 activation by EFV, 16 EFV analogs were employed.	efavirenz	85-88	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	56-65
30442673-8	2019	To further probe the structure-activity relationship of IRE1alpha-XBP1 activation by EFV, 16 EFV analogs were employed.	efavirenz	85-88	X-box binding protein 1	Mus musculus	66-70
31654514-8	2019	In the EFV-regimen group, TC, HDL-C, and LDL-C were increased compared to baseline, while the TC/HDL-C ratio decreased, and TG did not change significantly.	efavirenz	7-10	component of oligomeric golgi complex 2	Homo sapiens	41-46
31256164-9	2019	RESULTS: We observed significantly decreased CYP21A2 activity in both in vitro testing systems after treatment with efavirenz at therapeutic concentrations.	efavirenz	116-125	cytochrome P450 family 21 subfamily A member 2	Homo sapiens	45-52
29191071-4	2018	Efavirenz exhibited a type II spectral change with binding to CYP3A4 indicating a possible inhibitor.	efavirenz	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
29855606-5	2018	Composite CYP2B-mediated EFV metabolism was significantly associated with CNS toxicity (p = 0.04), with extensive metabolizers reporting more and slow and very slow metabolizers reporting less toxicity after 1 month compared to intermediate metabolizers.	efavirenz	25-28	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	10-15
30114293-6	2018	Efavirenz also reduced the efflux of calcein from MDCK-MRP2 cells, but had a rather weak inhibitory effect on Hoechst 33342 accumulation in MDCK-MDR1 and MDCK-BCRP cells.	efavirenz	0-9	ATP binding cassette subfamily C member 2	Canis lupus familiaris	55-59
30114293-6	2018	Efavirenz also reduced the efflux of calcein from MDCK-MRP2 cells, but had a rather weak inhibitory effect on Hoechst 33342 accumulation in MDCK-MDR1 and MDCK-BCRP cells.	efavirenz	0-9	ATP binding cassette subfamily B member 1	Canis lupus familiaris	145-149
30114293-6	2018	Efavirenz also reduced the efflux of calcein from MDCK-MRP2 cells, but had a rather weak inhibitory effect on Hoechst 33342 accumulation in MDCK-MDR1 and MDCK-BCRP cells.	efavirenz	0-9	ATP binding cassette subfamily G member 2	Canis lupus familiaris	159-163
30135687-4	2018	In this work, a longitudinal analysis was performed to evaluate APOBEC3G/3A expression in peripheral blood mononuclear cells of antiretroviral-naive HIV-1-infected individuals treated with cenicriviroc (CVC) or efavirenz (EFV) at baseline and 4, 12, 24, and 48 weeks post-treatment follow-up.	efavirenz	222-225	apolipoprotein B mRNA editing enzyme catalytic subunit 3G	Homo sapiens	64-72
29875890-8	2018	From EFV+AZT+3TC group, the mean CD4 cell count difference from baseline was 205(95% CI 155.404-235.623, p&lt; 0.001).	efavirenz	5-8	CD4 molecule	Homo sapiens	33-36
29661866-8	2018	In human hepatocytes and adipocytes, known target cells of FGF21 action, efavirenz, elvitegravir, and the lopinavir-ritonavir combination exerted inhibitory effects on KLB gene expression.	efavirenz	73-82	klotho beta	Homo sapiens	168-171
29430850-1	2018	Efavirenz (EFV), an antiretroviral that interacts clinically with co-administered drugs via activation of the pregnane X receptor (PXR), is extensively metabolized by the cytochromes P450.	efavirenz	0-9	nuclear receptor subfamily 1, group I, member 2	Mus musculus	110-129
29430850-1	2018	Efavirenz (EFV), an antiretroviral that interacts clinically with co-administered drugs via activation of the pregnane X receptor (PXR), is extensively metabolized by the cytochromes P450.	efavirenz	0-9	nuclear receptor subfamily 1, group I, member 2	Mus musculus	131-134
29430850-1	2018	Efavirenz (EFV), an antiretroviral that interacts clinically with co-administered drugs via activation of the pregnane X receptor (PXR), is extensively metabolized by the cytochromes P450.	efavirenz	11-14	nuclear receptor subfamily 1, group I, member 2	Mus musculus	110-129
29430850-1	2018	Efavirenz (EFV), an antiretroviral that interacts clinically with co-administered drugs via activation of the pregnane X receptor (PXR), is extensively metabolized by the cytochromes P450.	efavirenz	11-14	nuclear receptor subfamily 1, group I, member 2	Mus musculus	131-134
29430850-2	2018	We tested whether its primary metabolite, 8-hydroxyEFV (8-OHEFV) can activate PXR and potentially contribute to PXR-mediated drug-drug interactions attributed to EFV.	efavirenz	51-54	nuclear receptor subfamily 1, group I, member 2	Mus musculus	78-81
29430850-2	2018	We tested whether its primary metabolite, 8-hydroxyEFV (8-OHEFV) can activate PXR and potentially contribute to PXR-mediated drug-drug interactions attributed to EFV.	efavirenz	51-54	nuclear receptor subfamily 1, group I, member 2	Mus musculus	112-115
29430850-4	2018	Corroborating this, treatment with EFV for 72 h elevated the mRNA abundance of the PXR target gene, Cyp3a11, by approximately 28-fold in primary hepatocytes isolated from PXR-humanized mice, whereas treatment with 8-OHEFV did not result in a change in Cyp3A11 mRNA levels.	efavirenz	35-38	nuclear receptor subfamily 1, group I, member 2	Mus musculus	83-86
29430850-4	2018	Corroborating this, treatment with EFV for 72 h elevated the mRNA abundance of the PXR target gene, Cyp3a11, by approximately 28-fold in primary hepatocytes isolated from PXR-humanized mice, whereas treatment with 8-OHEFV did not result in a change in Cyp3A11 mRNA levels.	efavirenz	35-38	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	100-107
29430850-4	2018	Corroborating this, treatment with EFV for 72 h elevated the mRNA abundance of the PXR target gene, Cyp3a11, by approximately 28-fold in primary hepatocytes isolated from PXR-humanized mice, whereas treatment with 8-OHEFV did not result in a change in Cyp3A11 mRNA levels.	efavirenz	35-38	nuclear receptor subfamily 1, group I, member 2	Mus musculus	171-174
29430850-4	2018	Corroborating this, treatment with EFV for 72 h elevated the mRNA abundance of the PXR target gene, Cyp3a11, by approximately 28-fold in primary hepatocytes isolated from PXR-humanized mice, whereas treatment with 8-OHEFV did not result in a change in Cyp3A11 mRNA levels.	efavirenz	35-38	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	252-259
29430850-5	2018	FRET-based competitive binding assays and isothermal calorimetry demonstrated that even with the lack of ability to activate PXR, 8-OHEFV displays an affinity for PXR (IC50 12.1 mum; KD 7.9 mum) nearly identical to that of EFV (IC50 18.7 mum; KD 12.5 mum).	efavirenz	134-137	nuclear receptor subfamily 1, group I, member 2	Mus musculus	163-166
29629676-2	2018	EFV is metabolised in the liver via CYP2B6, and genetic polymorphism of CYP2B6 is known to result in slowed metabolism of the drug.	efavirenz	0-3	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	36-42
29098603-8	2018	The moderate CYP3A4 inducer efavirenz 400 mg or 600 mg q.d.	efavirenz	28-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
29629676-2	2018	EFV is metabolised in the liver via CYP2B6, and genetic polymorphism of CYP2B6 is known to result in slowed metabolism of the drug.	efavirenz	0-3	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	72-78
29636682-1	2018	Poor metabolisers of CYP2B6 (PM) require a lower dose of efavirenz because of serious adverse reactions resulting from the higher plasma concentrations associated with a standard dose.	efavirenz	57-66	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	21-27
28616806-3	2017	However, it is unknown whether SGLT2 inhibitors could reduce EFV in non-obese patients (BMI &lt;25 kg/m2) with type 2 diabetes.	efavirenz	61-64	solute carrier family 5 member 2	Homo sapiens	31-36
29190729-0	2017	Increased MMAB level in mitochondria as a novel biomarker of hepatotoxicity induced by Efavirenz.	efavirenz	87-96	metabolism of cobalamin associated B	Homo sapiens	10-14
29190729-8	2017	The expression levels of MMAB and ROS were detected in EFV-treated Huh-7 cells with and without shRNA used to knock down MMAB, and in primary hepatocytes (PHC).	efavirenz	55-58	metabolism of cobalamin associated B	Homo sapiens	25-29
29190729-15	2017	In addition, the liver of EFV-treated HIV infected patients showed substantially higher levels of MMAB expression compared to the livers of untreated or protease inhibitor (PI)-treated HIV-infected patients.	efavirenz	26-29	metabolism of cobalamin associated B	Homo sapiens	98-102
29190729-17	2017	MMAB was increased in EFV-treated Huh-7 cells and primary hepatocytes.	efavirenz	22-25	metabolism of cobalamin associated B	Homo sapiens	0-4
29534103-8	2018	RESULTS: In the CD4+ T-cell population, HIVpt affected 13/30 of patients on EFV versus 10/21 on ATV.	efavirenz	76-79	CD4 molecule	Homo sapiens	16-19
29534103-9	2018	In the CD4+CD45RO+ T-cell population, HIVpt was present in 14/30 of patients on EFV versus 15/21 on ATV.	efavirenz	80-83	CD4 molecule	Homo sapiens	7-10
29308748-6	2018	RESULTS: Both groups demonstrated a significant increase in their CD4+ T cell count which was greater in Zidovudine/Lamivudine and Efavirenz treated group.	efavirenz	131-140	CD4 molecule	Homo sapiens	66-69
29308748-8	2018	CONCLUSION: A rapid CD4+ Tcell increase occurred shortly after beginning ART consisting either Vonavir or combination of Zidovudine, Lamivudine and Efavirenz.	efavirenz	148-157	CD4 molecule	Homo sapiens	20-23
29308748-9	2018	Late increases in CD4+ T cell counts were more pronounced in therapy using Zidovudine/ Lamivudine and Efavirenz.	efavirenz	102-111	CD4 molecule	Homo sapiens	18-21
28874142-9	2017	In multivariate analysis, the variables independently associated with increased IFN-gamma production in response to PPD antigen were CD4+ T cell counts &lt;200 cells/mm3 at baseline, age, site of tuberculosis, 800 mg efavirenz dose and follow-up CD4+ T cell counts.	efavirenz	217-226	interferon gamma	Homo sapiens	80-89
28655608-3	2017	We enhanced CYP46A1 activity pharmacologically by treating 5XFAD mice, a model of rapid amyloidogenesis, with a low dose of the anti-HIV medication efavirenz.	efavirenz	148-157	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	12-19
28655608-6	2017	Nevertheless, efavirenz activated CYP46A1 and mouse cerebral cholesterol turnover during the first four months of administration.	efavirenz	14-23	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	34-41
28655608-11	2017	We suggest that CYP46A1 activation by efavirenz could be a new anti-Alzheimer"s disease treatment and a tool to study and identify normal and pathological brain processes affected by cholesterol maintenance.	efavirenz	38-47	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	16-23
28718515-8	2017	CYP2B6 516G T was significantly associated with EFV concentrations (p&lt;0.001).	efavirenz	48-51	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
28559276-4	2017	EFV concentration data were well described by a two-compartment model with first-order absorption (Ka ) and absorption lag time (Alag) (Ka = 0.2 h-1; Alag = 0.83 h; central compartment clearance [CLc/F] for CYP2B6*1/*1 = 18 liters/h, for CYP2B6*1/*6 = 14 liters/h, and for CYP2B6*6/*6 = 8.6 liters/h) and PBMCs as a peripheral compartment.	efavirenz	0-3	Charcot-Leyden crystal galectin	Homo sapiens	196-199
28481785-2	2017	Our objective was to investigate the relationship between the CYP2B6 516G&gt;T genotype and late virologic failure in patients treated with EFV in Gaborone, Botswana.	efavirenz	140-143	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	62-68
28481785-10	2017	CONCLUSION: The CYP2B6 516 T-allele was protective against late virologic breakthrough in patients with initial (6 month) HIV RNA suppression on EFV-based ART.	efavirenz	145-148	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
28559276-9	2017	CYP2B6*6 genotype polymorphisms were associated with decreased EFV and 8OHEFV clearance.	efavirenz	63-66	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
28456686-3	2017	Efavirenz was recently reported to interact in a similar concentration range with a number of receptors, transporters and ion channels including recombinant rat alpha1beta2gamma2 GABAA receptors whose actions were potentiated (Gatch et al., 2013; Dalwadi et al., 2016).	efavirenz	0-9	adrenoceptor alpha 1D	Homo sapiens	161-178
28194792-2	2017	In 12 healthy participants individual CYP3A activity was quantified using a semisimultaneous methodology (midazolam orally and 6 hours later intravenously) both alone and during a period of 22 days after a single oral dose of 400 mg efavirenz.	efavirenz	233-242	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
28403028-4	2017	RECENT FINDINGS: Dose adjustments of standard dose efavirenz are not necessary with rifampicin, because auto-induction of CYP2B6 by efavirenz counteracts the induction of rifampicin.	efavirenz	132-141	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	122-128
27599706-4	2017	METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs.	efavirenz	63-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
28642370-5	2017	We also found that l-Glu and other activating neurotransmitters bind to the same site on the CYP46A1 surface, which differs from the EFV-binding site.	efavirenz	133-136	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	93-100
28642370-6	2017	The other principal differences between EFV and l-Glu in CYP46A1 activation include an apparent lack of l-Glu binding to the P450 active site and different pathways of signal transduction from the allosteric site to the active site.	efavirenz	40-43	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	57-64
28642370-7	2017	EFV and l-Glu similarly increased the CYP46A1 kcat, the rate of the "fast" phase of the enzyme reduction by the redox partner NADPH-cytochrome P450 oxidoreductase, and the amount of P450 reduced.	efavirenz	0-3	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	38-45
28642370-8	2017	Spectral titrations with cholesterol, in the presence of EFV or l-Glu, suggest that water displacement from the heme iron can be affected in activator-bound CYP46A1.	efavirenz	57-60	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	157-164
28642370-9	2017	Moreover, EFV and l-Glu synergistically activated CYP46A1.	efavirenz	10-13	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	50-57
27599706-4	2017	METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs.	efavirenz	63-72	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	112-118
27599706-4	2017	METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs.	efavirenz	63-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
27599706-4	2017	METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs.	efavirenz	63-72	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	136-142
27799216-5	2017	Wistar rats were administered efavirenz (10 mg kg of body weight-1) once daily over 5 weeks.	efavirenz	30-39	Body weight QTL 17	Rattus norvegicus	58-66
28321215-3	2017	We found that IFN-lambdas synergistically enhanced anti-HIV activity of antiretrovirals [azidothymidine (AZT), efavirenz, indinavir, and enfuvirtide] in infected macrophages.	efavirenz	111-120	interferon alpha 1	Homo sapiens	14-17
27639578-6	2017	EFV-mediated toxicity is initiated with the permeabilization of mitochondrial outer membrane and change in mitochondrial membrane potential (Deltapsim) which triggers a series of events like cytochrome c release, alteration in mitochondrial morphology and mitochondria-mediated apoptosis.	efavirenz	0-3	cytochrome c, somatic	Homo sapiens	191-203
28143541-14	2017	The predicted CD4+ count for TDF/3TC/EFV was (B = +347.65 cells/mm3, P &lt; 0.001) whereas that of AZT/3TC/EFV was (B = +281.54 cells/mm3, P &lt; 0.001).	efavirenz	37-40	CD4 molecule	Homo sapiens	14-17
27872069-3	2017	While doravirine is a cytochrome P450 3A4 (CYP3A4) substrate, efavirenz induces CYP3A4; therefore, the pharmacokinetics of both drugs following a switch from efavirenz to doravirine were assessed.	efavirenz	62-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
27872069-6	2017	Following a 7-day washout, efavirenz was administered at 600 mg QD for 14 days (period 2).	efavirenz	27-36	period circadian regulator 2	Homo sapiens	80-88
27404500-9	2017	Efavirenz, stavudine and ritonavir significantly down-regulated the bioactivating CYP2R1 and up-regulated the catabolic CYP24A1.	efavirenz	0-9	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	82-88
27404500-9	2017	Efavirenz, stavudine and ritonavir significantly down-regulated the bioactivating CYP2R1 and up-regulated the catabolic CYP24A1.	efavirenz	0-9	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	120-127
27799204-8	2017	Apparent oral clearance of efavirenz was reduced by 25% and 51% in subjects predicted to have intermediate and slow CYP2B6 metabolizer status, respectively.	efavirenz	27-36	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	116-122
28836850-7	2016	Further, we found that EFV promoted increased lactate dehydrogenase (LDH) release, activation of p38 mitogen-activated protein kinase (MAPK), and increased Bax expression in cultured NSCs.	efavirenz	23-26	BCL2-associated X protein	Mus musculus	156-159
27903949-4	2017	The authors report 2 cases in which a possible drug-herb interaction may have led to virological breakthrough in patients who were maintained on the same regimen for many years, including lamivudine (3TC)/zidovudine (ZDV)/efavirenz (EFV) and emtricitabine (FTC)/tenofovir (TDF)/EFV, respectively.	efavirenz	222-231	sex determining region Y	Homo sapiens	273-276
27903949-4	2017	The authors report 2 cases in which a possible drug-herb interaction may have led to virological breakthrough in patients who were maintained on the same regimen for many years, including lamivudine (3TC)/zidovudine (ZDV)/efavirenz (EFV) and emtricitabine (FTC)/tenofovir (TDF)/EFV, respectively.	efavirenz	233-236	sex determining region Y	Homo sapiens	273-276
27903949-4	2017	The authors report 2 cases in which a possible drug-herb interaction may have led to virological breakthrough in patients who were maintained on the same regimen for many years, including lamivudine (3TC)/zidovudine (ZDV)/efavirenz (EFV) and emtricitabine (FTC)/tenofovir (TDF)/EFV, respectively.	efavirenz	278-281	sex determining region Y	Homo sapiens	273-276
27779789-4	2016	CNS toxicity occurring with the recommended standard dose of EFV remains a challenge and may in part be attributable to polymorphisms in cytochrome P450 (CYP) 2B6, the enzyme involved in the major metabolic pathway for converting EFV to inactive metabolites.	efavirenz	61-64	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	137-162
27779789-5	2016	Functionally deficient alleles of CYP2B6 such as CYP2B6*6, *18, and *22 may be responsible for significantly higher therapeutic concentrations of EFV at a standard dose of 600 mg/day.	efavirenz	146-149	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-40
27779789-5	2016	Functionally deficient alleles of CYP2B6 such as CYP2B6*6, *18, and *22 may be responsible for significantly higher therapeutic concentrations of EFV at a standard dose of 600 mg/day.	efavirenz	146-149	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	49-55
27098343-10	2016	When administered together with endogenous vitamin D metabolites, dexamethasone and efavirenz counteracted the 1,25D3 -mediated up-regulation of CYP24A1, which inactivates 1,25D3 .	efavirenz	84-93	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	145-152
27704562-8	2016	Subjects received a single oral dose of 1200 mg raltegravir co-administered with 600 mg efavirenz on Day 12 of Period 2.	efavirenz	88-97	period circadian regulator 2	Homo sapiens	111-119
27125860-9	2016	The study also calls for caution related to higher exposure to 8-OH-EFV during simultaneous coadministration of EFV and RIF-based anti-TB regimens, which may be associated with neurotoxicity, particularly in female patients and CYP2B6*6 carriers.	efavirenz	68-71	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	228-234
27422672-6	2016	Although bupropion and efavirenz have been used and are recommended by regulatory agencies as clinical CYP2B6 probe substrates for DDI studies, CYP3A4 contributes to the metabolism of both probes and is induced by all reference CYP2B6 inducers.	efavirenz	23-32	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	103-109
27600044-3	2016	Efavirenz, a nonnucleoside HIV-1 reverse transcriptase inhibitor, is mainly cleared by CYP2B6, an enzyme strongly inhibited in vitro by voriconazole.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	87-93
27333947-2	2016	Since EFV is metabolized by the cytochrome P450 (CYP) 2B6 enzyme, we hypothesized that EFV would lengthen the rate-corrected QT (QTcF) interval in carriers of the CYP2B6*6 decreased functional allele.	efavirenz	6-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	32-57
27333947-2	2016	Since EFV is metabolized by the cytochrome P450 (CYP) 2B6 enzyme, we hypothesized that EFV would lengthen the rate-corrected QT (QTcF) interval in carriers of the CYP2B6*6 decreased functional allele.	efavirenz	6-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	163-169
27333947-2	2016	Since EFV is metabolized by the cytochrome P450 (CYP) 2B6 enzyme, we hypothesized that EFV would lengthen the rate-corrected QT (QTcF) interval in carriers of the CYP2B6*6 decreased functional allele.	efavirenz	87-90	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	32-57
27333947-2	2016	Since EFV is metabolized by the cytochrome P450 (CYP) 2B6 enzyme, we hypothesized that EFV would lengthen the rate-corrected QT (QTcF) interval in carriers of the CYP2B6*6 decreased functional allele.	efavirenz	87-90	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	163-169
27333947-7	2016	RESULTS: EFV demonstrated a gene-dose effect and exceeded the FDA criteria for QTcF interval prolongation in CYP2B6*6/*6 carriers.	efavirenz	9-12	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	109-115
27646953-5	2016	CASES PRESENTATION: A first case was a 33 years-old female newly diagnosed HIV patient with CD4 count of 4 cells/muL (0 %), normal complete blood count, liver and renal function tests was started on co-formulated tenofovir/emtricitabine/efavirenz and prophylactic cotrimoxazole.	efavirenz	237-246	CD4 molecule	Homo sapiens	92-95
27333947-9	2016	EFV concentrations exceeding 0.4 mug/mL significantly inhibited outward hERG tail currents (P &lt; 0.05).	efavirenz	0-3	ETS transcription factor ERG	Homo sapiens	72-76
27333947-10	2016	CONCLUSIONS: This study demonstrates that homozygous carriers of CYP2B6*6 allele may be at increased risk for EFV-induced QTcF interval prolongation via inhibition of hERG.	efavirenz	110-113	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	65-71
27333947-10	2016	CONCLUSIONS: This study demonstrates that homozygous carriers of CYP2B6*6 allele may be at increased risk for EFV-induced QTcF interval prolongation via inhibition of hERG.	efavirenz	110-113	ETS transcription factor ERG	Homo sapiens	167-171
27124896-0	2016	Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.	efavirenz	99-108	GC vitamin D binding protein	Homo sapiens	25-50
27709010-5	2016	CYP2B6 has been demonstrated to play a role in the metabolism of 2%-10% of clinically used drugs including widely used antineoplastic agents cyclophosphamide and ifosfamide, anesthetics propofol and ketamine, synthetic opioids pethidine and methadone, and the antiretrovirals nevirapine and efavirenz, among others.	efavirenz	291-300	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
27216995-7	2016	Efavirenz induced a marked concentration-dependent increase in interleukin-8 expression and release whereas elvitregravir had little effect.	efavirenz	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	63-76
27627692-9	2016	On the other hand, HIV patients of African origin are predisposed to developing EFV-induced neuropsychiatric AEs due to specific CYP2B6 genetic variants causing impaired metabolism of EFV.	efavirenz	80-83	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	129-135
27627692-9	2016	On the other hand, HIV patients of African origin are predisposed to developing EFV-induced neuropsychiatric AEs due to specific CYP2B6 genetic variants causing impaired metabolism of EFV.	efavirenz	184-187	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	129-135
26655325-9	2016	Compared to noncarriers, individuals homozygous for CYP2B6*6 had ~109% increased EFV levels in hair (p = .016) and CYP2B6*18 heterozygotes demonstrated 82% higher EFV hair levels (p = .0006).	efavirenz	81-84	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	52-58
26655325-9	2016	Compared to noncarriers, individuals homozygous for CYP2B6*6 had ~109% increased EFV levels in hair (p = .016) and CYP2B6*18 heterozygotes demonstrated 82% higher EFV hair levels (p = .0006).	efavirenz	163-166	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	115-121
27067333-3	2016	The objective of this analysis was to support the selection of an appropriate dose for this younger pediatric population and to explore the impact of CYP2B6 genetic polymorphisms on EFV systemic exposures.	efavirenz	182-185	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	150-156
26797214-6	2016	Subjects receiving EFV-based cART had 47% and 44% lower atovaquone AUCtau than subjects not receiving cART at atovaquone doses of 750 mg BID and 1500 mg BID, respectively (P&lt;= .01).	efavirenz	19-22	BH3 interacting domain death agonist	Homo sapiens	153-156
27151598-0	2016	Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles.	efavirenz	62-71	lactotransferrin	Rattus norvegicus	79-90
26307135-4	2016	Median intact FGF23 tended to increase with past use of both nonnucleoside reverse-transcriptase inhibitors and protease inhibitors, but tended to decrease with recent use of either tenofovir, efavirenz or lopinavir.	efavirenz	193-202	fibroblast growth factor 23	Homo sapiens	14-19
26307135-8	2016	Lower levels of intact FGF23 with recent use of tenofovir, efavirenz or lopinavir may reflect their adverse effects on bone and vitamin D metabolism relative to other drugs in their respective drug classes.	efavirenz	59-68	fibroblast growth factor 23	Homo sapiens	23-28
26906233-4	2016	He was receiving treatment with efavirenz, emtricitabine and tenofovir, his CD4 count was 580/mm3 and HIV viral load was undetectable.	efavirenz	32-41	CD4 molecule	Homo sapiens	76-79
26891286-5	2016	Efavirenz (EFV) and nevirapine (NVP) are the major components of HAART both metabolized by CYP2B6, an enzyme that can potentially be inhibited or induced by compounds found in medicinal plant extracts.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	91-97
26891286-5	2016	Efavirenz (EFV) and nevirapine (NVP) are the major components of HAART both metabolized by CYP2B6, an enzyme that can potentially be inhibited or induced by compounds found in medicinal plant extracts.	efavirenz	11-14	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	91-97
27045425-4	2016	RESULTS: Simulated AUCs for 600 mg EFV dose were 1.2- and 2.4-times greater than the product label for Ugandans in general and CYP2B6*6/*6 genotypes respectively.	efavirenz	35-38	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	127-133
27045425-5	2016	EFV daily doses of 450 and 250 mg for Ugandans and CYP2B6*6/*6 genotypes, respectively, yielded simulated exposures comparable to the product label.	efavirenz	0-3	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	51-57
26945366-9	2016	Treatment with efavirenz rather than nevirapine was associated with increased risk of developing diabetes (hazard ratio 1.27 (95% confidence interval (CI): 1.10-1.46)) in a multivariate analysis adjusting for age, sex, body mass index, baseline CD4 count, viral load, NRTI backbone, and exposure to other diabetogenic medicines.	efavirenz	15-24	CD4 molecule	Homo sapiens	245-248
26681005-1	2015	CYP2B6 is a highly polymorphic isoenzyme involved in the metabolism of many drugs including cyclophosphamide, bupropion, and efavirenz.	efavirenz	125-134	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
26599973-8	2016	CYP2B6 activity was inhibited by 19 tryptamines, but weakly compared to efavirenz.	efavirenz	72-81	cytochrome P450, family 2, subfamily b, polypeptide 3	Rattus norvegicus	0-6
26779253-4	2015	The drug metabolizing enzyme (DME), CYP2B6, is primarily responsible for EFV metabolism with minor contributions by CYP1A2, CYP2A6, CYP3A4, CYP3A5, and UGT2B7.	efavirenz	73-76	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	36-42
26779253-7	2015	METHODS: SNPs in CYP1A2, CYP2B6, UGT2B7, and NR1I2 (PXR) were selected for genotyping among 222 Bantu-speaking South African HIV-infected patients receiving EFV-containing HAART.	efavirenz	157-160	nuclear receptor subfamily 1 group I member 2	Homo sapiens	52-55
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	efavirenz	102-111	interleukin 6	Homo sapiens	199-203
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	efavirenz	102-111	tumor necrosis factor	Homo sapiens	205-214
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	efavirenz	102-111	intercellular adhesion molecule 1	Homo sapiens	216-222
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	efavirenz	102-111	vascular cell adhesion molecule 1	Homo sapiens	224-230
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	efavirenz	102-111	selectin E	Homo sapiens	232-241
26531764-8	2016	CONCLUSION: In our study, naive patients starting tenofovir/emtricitabine or abacavir/lamivudine plus efavirenz showed after 48 weeks a significant and comparable decrease in serum concentrations of IL-6, TNF-alpha, ICAM-1, VCAM-1, Eselectin and P-selectin, while the mean level of hs-CRP did not change significantly in any group.	efavirenz	102-111	selectin P	Homo sapiens	246-256
26553012-1	2016	Efavirenz (EFV) is principally metabolized by CYP2B6 to 8-hydroxy-efavirenz (8OH-EFV) and to a lesser extent by CYP2A6 to 7-hydroxy-efavirenz (7OH-EFV).	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
26553012-1	2016	Efavirenz (EFV) is principally metabolized by CYP2B6 to 8-hydroxy-efavirenz (8OH-EFV) and to a lesser extent by CYP2A6 to 7-hydroxy-efavirenz (7OH-EFV).	efavirenz	11-14	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
26553012-6	2016	In individuals (n = 67) genotyped for CYP2B6, 2A6, and CYP3A metabolic pathways, 8OH-EFV/EFV ratios in plasma were an index of CYP2B6 phenotypic activity (P &lt; 0.0001), which was also reflected by phase II metabolites 8OH-EFV-glucuronide/EFV and 8OH-EFV-sulfate/EFV ratios.	efavirenz	85-88	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	127-133
26831894-2	2016	We describe four children presenting with serious, persistent central nervous system adverse events who were found to have elevated plasma efavirenz concentrations as a result of carrying CYP2B6 single nucleotide polymorphisms, known to play a role in the metabolism of EFV.	efavirenz	270-273	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	188-194
25988279-2	2015	In the present study, we explored facilitated transport of efavirenz (EFV, a non-nucleoside reverse transcriptase inhibitor) across BBB using phenylalanine anchored solid lipid nanoparticles (PA-SLN).	efavirenz	59-68	sarcolipin	Homo sapiens	195-198
26183311-7	2015	In vitro the triple medication efavirenz, tenofovir and emtricitabine leads to a reduced survival fraction and an increased activation of the DNA repair proteins H2AX, Nbs, Atm and 53BP1 in combination with ionizing radiation.	efavirenz	31-40	H2A.X variant histone	Homo sapiens	162-166
26183311-7	2015	In vitro the triple medication efavirenz, tenofovir and emtricitabine leads to a reduced survival fraction and an increased activation of the DNA repair proteins H2AX, Nbs, Atm and 53BP1 in combination with ionizing radiation.	efavirenz	31-40	nibrin	Homo sapiens	168-171
26183311-7	2015	In vitro the triple medication efavirenz, tenofovir and emtricitabine leads to a reduced survival fraction and an increased activation of the DNA repair proteins H2AX, Nbs, Atm and 53BP1 in combination with ionizing radiation.	efavirenz	31-40	ATM serine/threonine kinase	Homo sapiens	173-176
26183311-7	2015	In vitro the triple medication efavirenz, tenofovir and emtricitabine leads to a reduced survival fraction and an increased activation of the DNA repair proteins H2AX, Nbs, Atm and 53BP1 in combination with ionizing radiation.	efavirenz	31-40	tumor protein p53 binding protein 1	Homo sapiens	181-186
26050957-4	2015	We treated apolipoprotein E-null (ApoE(-/-)) mice with EFV (75 mg/kg/day) or vehicle, via oral gavage, for 35 days and quantified commonly measured preclinical markers of CVD (intima-media thickening, arterial stiffening) and plaque area.	efavirenz	55-58	apolipoprotein E	Mus musculus	11-27
26050957-4	2015	We treated apolipoprotein E-null (ApoE(-/-)) mice with EFV (75 mg/kg/day) or vehicle, via oral gavage, for 35 days and quantified commonly measured preclinical markers of CVD (intima-media thickening, arterial stiffening) and plaque area.	efavirenz	55-58	apolipoprotein E	Mus musculus	34-38
25948712-8	2015	Although efavirenz is known as a marker substrate for human CYP2B6, efavirenz was not oxidized by CYP2B6 but by CYP2C9 in monkeys.	efavirenz	9-18	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	60-66
25948712-8	2015	Although efavirenz is known as a marker substrate for human CYP2B6, efavirenz was not oxidized by CYP2B6 but by CYP2C9 in monkeys.	efavirenz	68-77	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	98-104
25948712-8	2015	Although efavirenz is known as a marker substrate for human CYP2B6, efavirenz was not oxidized by CYP2B6 but by CYP2C9 in monkeys.	efavirenz	68-77	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	112-118
25782332-8	2015	In EFV-based regimens (n = 1162), TDF was significantly associated with higher rates of virologic suppression than AZT (93.8% vs. 88.1%; weighted odds ratio: 2.15 (95% CI: 1.29-3.58; P = 0.003)).	efavirenz	3-6	sex determining region Y	Homo sapiens	34-37
26107645-12	2015	The frequency of CCTG (0.524) in patients with EFV plasma concentrations &lt; 1 mug/mL was significantly higher than that in other patient groups, while that of ACCT (0.733) was significantly higher in patients with EFV concentrations &gt; 4 mug/mL, relative to other patient groups.	efavirenz	47-50	chaperonin containing TCP1 subunit 3	Homo sapiens	17-21
25914645-8	2015	Cellular accumulation of efavirenz and darunavir was also assessed in SLC22A1-expressing KCL22 cells and reversibility of this accumulation was assessed using prazosin.	efavirenz	25-34	solute carrier family 22 member 1	Homo sapiens	70-77
26415139-6	2015	Thus, CYP2B6 is a crucial enzyme in the metabolism of antiretroviral drugs, efavirenz and nevirapine.	efavirenz	76-85	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	6-12
26288843-4	2015	METHODS: We genotyped CYP2A6, CYP2B6 and CYP3A4, which encode enzymes principally involved in EFV metabolism, from patients enrolled in the multinational SMART, FIRST and ESPRIT studies, for whom outcome data of treatment adherence was available.	efavirenz	94-97	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	22-28
26288843-4	2015	METHODS: We genotyped CYP2A6, CYP2B6 and CYP3A4, which encode enzymes principally involved in EFV metabolism, from patients enrolled in the multinational SMART, FIRST and ESPRIT studies, for whom outcome data of treatment adherence was available.	efavirenz	94-97	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-36
26288843-4	2015	METHODS: We genotyped CYP2A6, CYP2B6 and CYP3A4, which encode enzymes principally involved in EFV metabolism, from patients enrolled in the multinational SMART, FIRST and ESPRIT studies, for whom outcome data of treatment adherence was available.	efavirenz	94-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
26288843-8	2015	FINDINGS: Patients with highest pharmacogenetic risk, as defined by cumulative SNPs in CYP2A6, CYP2B6 and CYP3A4, have an increased risk of discontinuation of EFV containing therapy compared to patients with lower genetic risk scores (adjusted HR 1.9, 95% CI 1.2, 3.1, P = 0.009).	efavirenz	159-162	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	87-93
26288843-8	2015	FINDINGS: Patients with highest pharmacogenetic risk, as defined by cumulative SNPs in CYP2A6, CYP2B6 and CYP3A4, have an increased risk of discontinuation of EFV containing therapy compared to patients with lower genetic risk scores (adjusted HR 1.9, 95% CI 1.2, 3.1, P = 0.009).	efavirenz	159-162	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	95-101
26288843-8	2015	FINDINGS: Patients with highest pharmacogenetic risk, as defined by cumulative SNPs in CYP2A6, CYP2B6 and CYP3A4, have an increased risk of discontinuation of EFV containing therapy compared to patients with lower genetic risk scores (adjusted HR 1.9, 95% CI 1.2, 3.1, P = 0.009).	efavirenz	159-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
30222398-8	2015	In multivariate analysis, efavirenz-based regimens showed more likelihood of immunologic recovery, whether defined as a CD4 cell count of &gt;200 cells/mm3 (hazard ratio [HR] = 1.31 [95% CI, 1.05-1.59]), &gt;350 cells/mm3 (HR = 1.26 [95% CI, 1.08-1.47]), or &gt;500 cells/mm3 (HR = 1.95 [95% CI, 1.57-2.41]).	efavirenz	26-35	CD4 molecule	Homo sapiens	120-123
25906774-2	2015	EFV, NVP, artemether and lumefantrine are substrates, inhibitors or inducers of CYP3A4 and CYP2B6, creating a potential for drug-drug interactions.	efavirenz	0-3	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	91-97
25914645-11	2015	Absolute SLC22A1 IC50 values for efavirenz, darunavir, and prazosin were 21.8, 46.2, and 2.8 muM, respectively.	efavirenz	33-42	solute carrier family 22 member 1	Homo sapiens	9-16
25914645-11	2015	Absolute SLC22A1 IC50 values for efavirenz, darunavir, and prazosin were 21.8, 46.2, and 2.8 muM, respectively.	efavirenz	33-42	latexin	Homo sapiens	93-96
25914645-12	2015	Efavirenz accumulation was higher in SLC22A1-expressing cells compared to mock-transfected cells (17% higher, p = 0.009) which was reversed using prazosin, whereas no difference was observed for darunavir (p = 0.86).	efavirenz	0-9	solute carrier family 22 member 1	Homo sapiens	37-44
25096076-0	2014	Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4beta-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.	efavirenz	107-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-58
25914645-7	2015	SLC22A1 IC50 values for efavirenz, darunavir, and prazosin were determined.	efavirenz	24-33	solute carrier family 22 member 1	Homo sapiens	0-7
25733917-4	2015	As a substrate of CYP 3A4, dolutegravir is affected by rifampin, efavirenz, tipranavir/ritonavir, fosamprenavir/ritonavir, and dose increase is required.	efavirenz	65-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-25
25777186-9	2015	The mean changes from baseline in CD4 count were similar in both rilpivirine and efavirenz (RR = 1.05, 95% CI: 0.85-1.24).	efavirenz	81-90	CD4 molecule	Homo sapiens	34-37
25889207-8	2015	RESULTS: CYP2B6*6 and *18 variant alleles, weight and sex were the most significant covariates explaining 55% of inter-individual variability in EFV clearance.	efavirenz	145-148	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	9-15
25321623-10	2015	In the EFV/FTC/TDF group, virus from 14 patients (4.0%; 14/352 treated patients; 4 during weeks 96-144) developed a resistance substitution to EFV (n=14; K103N: n=13), FTC (M184V/I: n=4) or TDF (K65R: n=3).	efavirenz	7-10	sex determining region Y	Homo sapiens	190-193
26699137-8	2015	RESULTS: A 48 hours exposure of human erythrocytes to efavirenz (&gt;= 2 microg/ml) significantly increased the percentage of annexin-V-binding cells, significantly decreased forward scatter (2 microg/ml), significantly increased Fluo3-fluorescence (&gt;= 2 microg/ml), but did not significantly modify DCFDA fluorescence or ceramide abundance.	efavirenz	54-63	annexin A5	Homo sapiens	126-135
26699137-9	2015	The effect of efavirenz on annexin-V-binding was significantly blunted, but not abolished by removal of extracellular Ca2+.	efavirenz	14-23	annexin A5	Homo sapiens	27-36
26699137-10	2015	The effect of efavirenz on annexin-V-binding was further significantly blunted by p38 kinase inhibitor SB203580 (2 microM) and casein kinase 1alpha inhibitor D4476 (10 microM), but not by cyclooxygenase inhibitor aspirin (50 microM).	efavirenz	14-23	annexin A5	Homo sapiens	27-36
25625582-7	2015	Furthermore, EFV resulted in increased formation of peroxynitrite and oxidation of mitochondrial protein thiols, including cyclophilin D (CypD).	efavirenz	13-16	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	123-136
25625582-7	2015	Furthermore, EFV resulted in increased formation of peroxynitrite and oxidation of mitochondrial protein thiols, including cyclophilin D (CypD).	efavirenz	13-16	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	138-142
25625582-10	2015	Finally, EFV increased the NADH/NAD(+) ratio, inhibited Sirt3 activity, and led to hyperacetylated lysine residues, including those in CypD.	efavirenz	9-12	sirtuin 3	Mus musculus	56-61
25625582-10	2015	Finally, EFV increased the NADH/NAD(+) ratio, inhibited Sirt3 activity, and led to hyperacetylated lysine residues, including those in CypD.	efavirenz	9-12	peptidylprolyl isomerase F (cyclophilin F)	Mus musculus	135-139
25625582-11	2015	However, hepatocytes isolated from Sirt3-null mice were protected against 40microM EFV as compared to their wild-type controls.	efavirenz	83-86	sirtuin 3	Mus musculus	35-40
25096076-7	2014	Efavirenz treatment in arm 1 resulted in 1.74 (relative standard error = 15%), 3.3 (relative standard error = 33.1%) and 4.0 (relative standard error = 37.1%) average fold induction of CYP3A for extensive (CYP2B6*1/*1), intermediate (CYP2B6*1/*6) and slow (CYP2B6*6/*6) efavirenz metabolizers, respectively.	efavirenz	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-190
25096076-7	2014	Efavirenz treatment in arm 1 resulted in 1.74 (relative standard error = 15%), 3.3 (relative standard error = 33.1%) and 4.0 (relative standard error = 37.1%) average fold induction of CYP3A for extensive (CYP2B6*1/*1), intermediate (CYP2B6*1/*6) and slow (CYP2B6*6/*6) efavirenz metabolizers, respectively.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	206-212
25096076-7	2014	Efavirenz treatment in arm 1 resulted in 1.74 (relative standard error = 15%), 3.3 (relative standard error = 33.1%) and 4.0 (relative standard error = 37.1%) average fold induction of CYP3A for extensive (CYP2B6*1/*1), intermediate (CYP2B6*1/*6) and slow (CYP2B6*6/*6) efavirenz metabolizers, respectively.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	234-240
25096076-7	2014	Efavirenz treatment in arm 1 resulted in 1.74 (relative standard error = 15%), 3.3 (relative standard error = 33.1%) and 4.0 (relative standard error = 37.1%) average fold induction of CYP3A for extensive (CYP2B6*1/*1), intermediate (CYP2B6*1/*6) and slow (CYP2B6*6/*6) efavirenz metabolizers, respectively.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	234-240
25096076-10	2014	CONCLUSIONS: Our results indicate that efavirenz induction of CYP3A is influenced by CYP2B6 genetic polymorphisms and that efavirenz/rifampicin co-treatment results in higher induction than efavirenz alone.	efavirenz	39-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-67
25096076-10	2014	CONCLUSIONS: Our results indicate that efavirenz induction of CYP3A is influenced by CYP2B6 genetic polymorphisms and that efavirenz/rifampicin co-treatment results in higher induction than efavirenz alone.	efavirenz	39-48	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	85-91
25355844-4	2014	Patients received 600 mg efavirenz daily with the possibility of a dose increase in case of PSA progression.	efavirenz	25-34	kallikrein related peptidase 3	Homo sapiens	92-95
25355844-7	2014	The exploratory analysis revealed that for the 7 patients in whom optimal plasma concentration of efavirenz was achieved, PSA progression was observed in only 28.6% compared with 81.8% of patients with suboptimal plasma concentrations of efavirenz.	efavirenz	98-107	kallikrein related peptidase 3	Homo sapiens	122-125
25394049-8	2014	Whilst CSF efavirenz concentration was significantly associated with plasma concentration (P&lt;0.001) and CYP2B6 genotype (CSF efavirenz GG to GT/TT GM ratio 0.56, 90% CI 0.42-0.74), CSF 8OH-efavirenz concentration was not (P=0.242 for association with plasma concentration and CSF 8OH-efavirenz GG to GT/TT GM ratio 1.52, 90% CI 0.97-2.36).	efavirenz	11-20	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	107-113
25433665-9	2014	The mean changes from baseline in CD4 count were similar in both rilpivirine and efavirenz (RR, 1.05; 95% CI, 0.85-1.24).	efavirenz	81-90	CD4 molecule	Homo sapiens	34-37
24820076-0	2014	Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.	efavirenz	71-80	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	23-29
25309681-1	2014	Cytochrome P450 2B6 (CYP2B6) is primarily responsible for the metabolism of the anti-HIV drug efavirenz (EFV).	efavirenz	105-108	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-19
25309681-1	2014	Cytochrome P450 2B6 (CYP2B6) is primarily responsible for the metabolism of the anti-HIV drug efavirenz (EFV).	efavirenz	105-108	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	21-27
25309681-2	2014	We set out to explore the molecular basis for CYP2B6 activity toward EFV by examining the metabolism of eight EFV analogues.	efavirenz	69-72	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
25309681-4	2014	Subsequent substrate depletion analysis of EFV and EFV analogues found to be CYP2B6 substrates revealed further differences between these CYP2B6 substrates.	efavirenz	43-46	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	77-83
25309681-4	2014	Subsequent substrate depletion analysis of EFV and EFV analogues found to be CYP2B6 substrates revealed further differences between these CYP2B6 substrates.	efavirenz	43-46	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	138-144
25309681-4	2014	Subsequent substrate depletion analysis of EFV and EFV analogues found to be CYP2B6 substrates revealed further differences between these CYP2B6 substrates.	efavirenz	51-54	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	77-83
25309681-4	2014	Subsequent substrate depletion analysis of EFV and EFV analogues found to be CYP2B6 substrates revealed further differences between these CYP2B6 substrates.	efavirenz	51-54	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	138-144
24820106-7	2014	MtDNA and cytochrome oxidase subunit II did not change, and cytochrome b increased significantly in EFV-treated patients.	efavirenz	100-103	mitochondrially encoded cytochrome b	Homo sapiens	60-72
24729492-9	2014	Fewer (P &lt; .001) RPV-treated patients than EFV-treated patients had TC, LDL-C, and triglyceride levels above National Cholesterol Education Program cutoffs.	efavirenz	46-49	component of oligomeric golgi complex 2	Homo sapiens	75-80
24846165-3	2014	Treatments of HIV patients with CML are with HAART drugs, ritonavir and efavirenz, may cause complex drug interactions through CYP3A inhibition or induction.	efavirenz	72-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-132
24820076-0	2014	Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.	efavirenz	71-80	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	155-161
24164392-7	2014	Patients receiving efavirenz had higher levels of L-FABP/creatinine in comparison to healthy controls (p=0.0039).	efavirenz	19-28	fatty acid binding protein 1	Homo sapiens	50-56
24956253-2	2014	The aim of this study was to evaluate the clinical and economic impact of efavirenz (EFV) dose adjustment by monitoring plasma concentrations and pharmacogenetic analysis of the 516G&gt;T CYP2B6 polymorphism.	efavirenz	74-83	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	188-194
24956253-2	2014	The aim of this study was to evaluate the clinical and economic impact of efavirenz (EFV) dose adjustment by monitoring plasma concentrations and pharmacogenetic analysis of the 516G&gt;T CYP2B6 polymorphism.	efavirenz	85-88	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	188-194
24474568-12	2014	Efavirenz, a potent inducer of CYP3A4, resulted in increased exposure of N-desethyl sunitinib, whereas ritonavir caused decreased exposure of the metabolite.	efavirenz	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-37
24488374-15	2014	The CYP3A4 inducers efavirenz and dexamethasone did not have a significant effect on docetaxel exposure (AUC).	efavirenz	20-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
24352658-3	2014	We found that four pharmaceuticals (efavirenz (EFV), acetaminophen, mirtazapine, and galantamine) prescribed for indications unrelated to cholesterol maintenance increased CYP46A1 activity in vitro.	efavirenz	36-45	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	172-179
24390631-6	2014	Ethnic differences and the associated prevalence of CYP2B6 polymorphisms result in significant differences in the PKPD associated with a standard 600 mg per day dose of EFV, warranting dosage reduction in carriers of specific CYP2B6 polymorphisms.	efavirenz	169-172	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	52-58
24390631-6	2014	Ethnic differences and the associated prevalence of CYP2B6 polymorphisms result in significant differences in the PKPD associated with a standard 600 mg per day dose of EFV, warranting dosage reduction in carriers of specific CYP2B6 polymorphisms.	efavirenz	169-172	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	226-232
24275118-0	2014	Efavirenz induces interactions between leucocytes and endothelium through the activation of Mac-1 and gp150,95.	efavirenz	0-9	integrin subunit alpha M	Homo sapiens	92-97
24275118-0	2014	Efavirenz induces interactions between leucocytes and endothelium through the activation of Mac-1 and gp150,95.	efavirenz	0-9	integrin subunit beta 4	Homo sapiens	102-110
24275118-7	2014	Efavirenz, but not nevirapine, augmented the levels of CD11b, CD11c and CD18 in neutrophils and monocytes.	efavirenz	0-9	integrin subunit alpha M	Homo sapiens	55-60
24275118-7	2014	Efavirenz, but not nevirapine, augmented the levels of CD11b, CD11c and CD18 in neutrophils and monocytes.	efavirenz	0-9	integrin subunit alpha X	Homo sapiens	62-67
24275118-7	2014	Efavirenz, but not nevirapine, augmented the levels of CD11b, CD11c and CD18 in neutrophils and monocytes.	efavirenz	0-9	integrin subunit beta 2	Homo sapiens	72-76
24759994-3	2014	Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Abeta), and promoted increased beta-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints.	efavirenz	15-18	beta-site APP cleaving enzyme 1	Mus musculus	136-152
24759994-3	2014	Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Abeta), and promoted increased beta-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints.	efavirenz	15-18	beta-site APP cleaving enzyme 1	Mus musculus	154-160
24759994-3	2014	Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Abeta), and promoted increased beta-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints.	efavirenz	26-29	beta-site APP cleaving enzyme 1	Mus musculus	136-152
24759994-3	2014	Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Abeta), and promoted increased beta-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints.	efavirenz	26-29	beta-site APP cleaving enzyme 1	Mus musculus	154-160
24759994-6	2014	EFV or the EFV containing regimen promoted significantly more BACE-1 expression and soluble Abeta generation while 3TC, AZT, or vehicle control did not.	efavirenz	0-3	beta-site APP cleaving enzyme 1	Mus musculus	62-68
24759994-6	2014	EFV or the EFV containing regimen promoted significantly more BACE-1 expression and soluble Abeta generation while 3TC, AZT, or vehicle control did not.	efavirenz	11-14	beta-site APP cleaving enzyme 1	Mus musculus	62-68
23629159-0	2014	Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.	efavirenz	0-9	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	57-64
23629159-2	2014	We hypothesized that CYP2C19 and CYP2B6 genetic polymorphisms influence the extent of induction of omeprazole metabolism by efavirenz.	efavirenz	124-133	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	21-28
23629159-2	2014	We hypothesized that CYP2C19 and CYP2B6 genetic polymorphisms influence the extent of induction of omeprazole metabolism by efavirenz.	efavirenz	124-133	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	33-39
24589015-11	2014	IP-10 and MIG levels declined significantly less strongly with ATV/r than with EFV (IP-10Delta -57%, p = 0.011; MIGDelta -136%, p = 0.007), while no difference was noted between LPV/r and EFV.	efavirenz	79-82	C-X-C motif chemokine ligand 10	Homo sapiens	0-5
24589015-11	2014	IP-10 and MIG levels declined significantly less strongly with ATV/r than with EFV (IP-10Delta -57%, p = 0.011; MIGDelta -136%, p = 0.007), while no difference was noted between LPV/r and EFV.	efavirenz	79-82	C-X-C motif chemokine ligand 9	Homo sapiens	10-13
24352658-3	2014	We found that four pharmaceuticals (efavirenz (EFV), acetaminophen, mirtazapine, and galantamine) prescribed for indications unrelated to cholesterol maintenance increased CYP46A1 activity in vitro.	efavirenz	47-50	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	172-179
24316028-1	2014	Efavirenz (EFV) exhibits interindividual pharmacokinetic variability caused by differences in cytochrome P450 (CYP) expression.	efavirenz	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-109
24316028-1	2014	Efavirenz (EFV) exhibits interindividual pharmacokinetic variability caused by differences in cytochrome P450 (CYP) expression.	efavirenz	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-114
24316028-3	2014	We investigated in patients co-infected with human immunodeficiency virus (HIV) and TB recruited in Rwanda the effects of 10 SNPs in five drug-metabolizing enzymes on EFV plasma levels and treatment response when patients are treated with EFV-containing therapy alone (n=28) and when combined with rifampicin-based TB treatment (n=62), and the validity of genotyping for CYP2B6 single nucleotide polymorphisms in predicting supra-therapeutic EFV levels.	efavirenz	239-242	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	371-377
24316028-3	2014	We investigated in patients co-infected with human immunodeficiency virus (HIV) and TB recruited in Rwanda the effects of 10 SNPs in five drug-metabolizing enzymes on EFV plasma levels and treatment response when patients are treated with EFV-containing therapy alone (n=28) and when combined with rifampicin-based TB treatment (n=62), and the validity of genotyping for CYP2B6 single nucleotide polymorphisms in predicting supra-therapeutic EFV levels.	efavirenz	239-242	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	371-377
24316028-4	2014	There was a significant difference between CYP1A2 -739T/G and T/T genotypes when patients were treated with EFV-containing therapy combined with rifampicin-based TB treatment, but not when EFV-containing therapy was alone.	efavirenz	108-111	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	43-49
24316028-6	2014	Predictive factors of EFV plasma levels in the presence of rifampicin-based TB treatment were CYP2A6 1093G&gt;A, CYP2B6 516G&gt;T, and CYP2B6 983T&gt;C accounting for 27%, 43%, and 29% of the total variance in EFV levels, respectively.	efavirenz	22-25	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	94-100
24316028-6	2014	Predictive factors of EFV plasma levels in the presence of rifampicin-based TB treatment were CYP2A6 1093G&gt;A, CYP2B6 516G&gt;T, and CYP2B6 983T&gt;C accounting for 27%, 43%, and 29% of the total variance in EFV levels, respectively.	efavirenz	22-25	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	113-119
24316028-6	2014	Predictive factors of EFV plasma levels in the presence of rifampicin-based TB treatment were CYP2A6 1093G&gt;A, CYP2B6 516G&gt;T, and CYP2B6 983T&gt;C accounting for 27%, 43%, and 29% of the total variance in EFV levels, respectively.	efavirenz	22-25	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	135-141
24316028-7	2014	There was a high positive predictive value (PPV) (100%) for CYP2B6 516T/T and 983T/T genotypes in predicting EFV plasma levels above the therapeutic range, but this PPV decreased in the presence of rifampicin-based TB treatment.	efavirenz	109-112	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	60-66
23990572-0	2014	Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.	efavirenz	14-23	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	108-114
23990572-0	2014	Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.	efavirenz	14-23	N-acetyltransferase 2	Homo sapiens	119-123
24497997-8	2014	RESULTS: EFV apparent clearance (CL/F) was 2.2 and 1.74 fold higher in CYP2B6*6 (*1/*1) and CYP2B6*6 (*1/*6) compared CYP2B6*6 (*6/*6) carriers, while a 22% increase in F1 was observed for carriers of ABCB1 c.4046A&gt;G variant allele.	efavirenz	9-12	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	71-77
24497997-8	2014	RESULTS: EFV apparent clearance (CL/F) was 2.2 and 1.74 fold higher in CYP2B6*6 (*1/*1) and CYP2B6*6 (*1/*6) compared CYP2B6*6 (*6/*6) carriers, while a 22% increase in F1 was observed for carriers of ABCB1 c.4046A&gt;G variant allele.	efavirenz	9-12	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	92-98
24497997-8	2014	RESULTS: EFV apparent clearance (CL/F) was 2.2 and 1.74 fold higher in CYP2B6*6 (*1/*1) and CYP2B6*6 (*1/*6) compared CYP2B6*6 (*6/*6) carriers, while a 22% increase in F1 was observed for carriers of ABCB1 c.4046A&gt;G variant allele.	efavirenz	9-12	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	92-98
24497997-8	2014	RESULTS: EFV apparent clearance (CL/F) was 2.2 and 1.74 fold higher in CYP2B6*6 (*1/*1) and CYP2B6*6 (*1/*6) compared CYP2B6*6 (*6/*6) carriers, while a 22% increase in F1 was observed for carriers of ABCB1 c.4046A&gt;G variant allele.	efavirenz	9-12	ATP binding cassette subfamily B member 1	Homo sapiens	201-206
24268674-2	2014	Efavirenz, neviparine, darunavir and atazanavir increased nitric oxide (NO) production in microglial cells activated with Gp120CN54 and interferon-gamma.	efavirenz	0-9	interferon gamma	Rattus norvegicus	136-152
24142869-8	2014	The final model included only CYP2B6 genotype as a covariate that predicts EFV clearance through the formation of 8-OH EFV that represented 65% to 80% of EFV clearance.	efavirenz	75-78	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-36
24142869-8	2014	The final model included only CYP2B6 genotype as a covariate that predicts EFV clearance through the formation of 8-OH EFV that represented 65% to 80% of EFV clearance.	efavirenz	119-122	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-36
24142869-9	2014	The total clearance of EFV in CYP2B6*6/*6 genotype was ~30% lower than CYP2B6*1/*1 or CYP2B6*1/*6 alleles (P &lt; .001).	efavirenz	23-26	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-36
24091996-5	2013	In contrast, the primary metabolite of efavirenz, 8-hydroxy-efavirenz, stimulated the glycolytic flux in viable astrocytes in a time- and concentration-dependent manner with half-maximal and maximal effects at concentrations of 5 and 10 muM, respectively.	efavirenz	39-48	latexin	Homo sapiens	237-240
23836171-8	2013	Amprenavir, atazanavir, darunavir, efavirenz, ritonavir, and lopinavir were found to activate hPXR, whereas abacavir, efavirenz, and nevirapine were found to activate hCAR.	efavirenz	35-44	nuclear receptor subfamily 1 group I member 2	Homo sapiens	94-98
23836171-8	2013	Amprenavir, atazanavir, darunavir, efavirenz, ritonavir, and lopinavir were found to activate hPXR, whereas abacavir, efavirenz, and nevirapine were found to activate hCAR.	efavirenz	35-44	CXADR Ig-like cell adhesion molecule	Homo sapiens	167-171
23836171-8	2013	Amprenavir, atazanavir, darunavir, efavirenz, ritonavir, and lopinavir were found to activate hPXR, whereas abacavir, efavirenz, and nevirapine were found to activate hCAR.	efavirenz	118-127	CXADR Ig-like cell adhesion molecule	Homo sapiens	167-171
24372550-5	2014	KEY RESULTS: Direct LBD interactions with LXRalpha and/or LXRbeta were predicted in silico and confirmed in vitro for darunavir, efavirenz, flavopiridol, maraviroc and tipranavir.	efavirenz	129-138	nuclear receptor subfamily 1 group H member 3	Homo sapiens	42-50
24372550-5	2014	KEY RESULTS: Direct LBD interactions with LXRalpha and/or LXRbeta were predicted in silico and confirmed in vitro for darunavir, efavirenz, flavopiridol, maraviroc and tipranavir.	efavirenz	129-138	nuclear receptor subfamily 1 group H member 2	Homo sapiens	58-65
23846872-3	2013	Efavirenz clearance was predictable using in vitro data for carriers of the CYP2B6*1/*1 genotype, but the prediction in carriers of the CYP2B6*6 allele was poor.	efavirenz	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	76-82
24521642-9	2013	Logistic regression analysis showed CYP2B6 516G&gt;T polymorphism significantly associated with virologic outcome in patients receiving EFV-based regimen.	efavirenz	136-139	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	36-42
24334181-1	2013	BACKGROUND: ACTG A5202 randomized treatment-naive individuals to tenofovir-emtricitabine (TDF/FTC) or abacavir-lamivudine (ABC/3TC) combined with efavirenz (EFV) or atazanavir/ritonavir (ATV/r).	efavirenz	146-155	actin gamma 1	Homo sapiens	12-16
24334181-1	2013	BACKGROUND: ACTG A5202 randomized treatment-naive individuals to tenofovir-emtricitabine (TDF/FTC) or abacavir-lamivudine (ABC/3TC) combined with efavirenz (EFV) or atazanavir/ritonavir (ATV/r).	efavirenz	157-160	actin gamma 1	Homo sapiens	12-16
23937548-1	2013	The fixed-dose combination efavirenz, emtricitabine, and tenofovir (EFV/FTC/TDF) is a first-line agent for the treatment of HIV.	efavirenz	27-36	sex determining region Y	Homo sapiens	76-79
23612009-8	2013	Furthermore, the effect of EFV on the phosphorylation state of the growth factors Erk, Akt and the tumour suppressor protein p53 was tested.	efavirenz	27-30	mitogen-activated protein kinase 1	Homo sapiens	82-85
23612009-14	2013	Furthermore, EFV led to an activating phosphorylation of the tumour suppressor protein p53 going in line with earlier reports that EFV may be antitumourigenic and a potential cytostatic drug.	efavirenz	13-16	tumor protein p53	Homo sapiens	87-90
23612009-14	2013	Furthermore, EFV led to an activating phosphorylation of the tumour suppressor protein p53 going in line with earlier reports that EFV may be antitumourigenic and a potential cytostatic drug.	efavirenz	131-134	tumor protein p53	Homo sapiens	87-90